

April 22, 2015

---

Signature

**PRANATHARTHI HARAN CHANDRASEKAR, M.D.**

**ADDRESS**

Division of Infectious Diseases  
Department of Internal Medicine  
Harper University Hospital  
3990 John R, 5 Hudson, Room 5911  
Detroit, MI 48201  
Ph: (313) 745-7105  
Fax: (313) 993-0302  
Email: [pchandrasedkar@med.wayne.edu](mailto:pchandrasedkar@med.wayne.edu)

**EDUCATION**

MBBS, Christian Medical College, Vellore, India	1973
Pre-University Certificate, Madurai College, Madurai, India	1968
Certificate of Education, (Advanced Level), St. Benedict's College, Colombo, Sri Lanka	1967

**POSTGRADUATE TRAINING**

Fellow, Division of Infectious Diseases, Hahnemann University of Louisville, Louisville, KY	1981 – 1983
Resident, Department of Internal Medicine, University of Louisville, Louisville, KY	1980 – 1981
Resident, Department of Internal Medicine, St. Francis Medical Center, Trenton, NJ	1978 – 1980
Resident, Department of Psychiatry, Downstate Medical Center, Brooklyn, NY	1977
Research Fellow, Internal Medicine, Christian Medical College, Vellore, India	1975
Senior House Officer, (Cardiology, Neurology, and Ophthalmology), Christian Medical College, Vellore, India	1975
Rotating Intern, Christian Medical College, Vellore, India	1974 – 1975

### **FACULTY APPOINTMENTS**

Professor, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI	1996 – Present
Associate Professor, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI	1989 – 1996
Assistant Professor, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI	1983 – 1989

### **HOSPITAL OR OTHER PROFESIONAL APPOINTMENTS**

<b>Chief, Infectious Disease, Department of Internal Medicine, Wayne State University School of Medicine</b>	<b>2014 – Present</b>
<b>Compensation Committee, Department of Medicine, Wayne State University</b>	<b>2014 - Present</b>
Compensation Committee, Department of Medicine, Wayne State University	2008
<b>Chief, Infectious Diseases, Karmanos Cancer Institute</b>	<b>2006 – Present</b>
Board of Directors, Affiliated Internists, Department of Medicine, Wayne State University	2002 – 2007
Renaissance Home Health Care – Member, Medical Advisory Board	1997 – 2005
International Committee on Infections in Transplant Recipients, Immunocompromised Host Society	1994 – 2000
Program director, Infectious Diseases Fellowship, Wayne State University	1993 – 2014
Member, Medical Advisory Committee, Harper University Hospital	1993 – 2002
AIDS Task Force, Detroit Medical Center	1989 – 1996
Vice-Chairman, Infection Control Committee, Harper University Hospital	1989 – 1995
Infection Control Committee, Detroit Receiving Hospital	1983 – 1989
Pharmacy and Therapeutics Committee, Detroit Receiving Hospital	1983 – 1989
Medical Director, Detroit Center for Clinical Studies, Detroit, MI (Pharmakinetix Laboratories, Baltimore, MD)	1983 – 1984

### **MAJOR PROFESSIONAL SOCIETIES**

<b>American College of Physicians, Fellow</b>	<b>– Present</b>
<b>Infectious Diseases Society of America, Fellow</b>	<b>– Present</b>
<b>American Society of Microbiology, Member</b>	<b>– Present</b>
<b>International Immunocompromised Host Society, Member</b>	<b>– Present</b>

### **MEDICAL LICENSURE**

ECFMG Certification 0-220-351-1 Active: Michigan	Aug. 24, 1983
---	---------------

### **BOARD CERTIFICATION**

Diplomate, American Board of internal Medicine, Number 83599	Sept. 16, 1981
Diplomate, Infectious Diseases, American Board of Internal Medicine, Number 83599	Nov. 13, 1984

### **HONORS / AWARDS**

<b>Clinician Teacher Award (Michigan Infectious Disease Society)</b>	<b>2015</b>
<b>Top Docs (Hour Detroit Magazine)</b>	<b>2010– 2014</b>
<b>Best Doctors in America</b>	<b>2000 – 2014</b>
Merck Mycology Award – Immunocompromised Host Society	2000
Benjamin Pulimood Oration, Christian Medical College, Vellore	2000
Leadership and Teaching Excellence College Teaching Award	2005
Leadership and Teaching Excellence College Teaching Award	1999
Departmental Teaching Award	1999

### **SERVICE**

#### Wayne State University

Search Committee for the position of Chairman, Department of Internal Medicine	2007
--	------

#### Affiliate Medical Organization: Karmanos Cancer Institute

Chair, Search Committee for the position of Division Chief in Hematology/Oncology	2006
---	------

#### Professional

<b>Michigan Infectious Diseases Society, Councilor to Board of Trustees</b>	<b>2014 – Present</b>
<b>National Board of Medical Examiners – Infectious Diseases Society of America In-Training Exam: Item-Writing Committee, Vice Chair</b>	<b>2007 – Present</b>

Professional (continued)

Reviewer – Guidelines for the Prevention of Opportunistic Infections in  
In Bone marrow Transplant Recipients, Department of Health & Human Services,  
Centers for Disease Control and Prevention 1999

Ad Hoc Advisory Committee on HIV-Infected Health Care Workers, State of Michigan 1991

**Infectious Diseases Protocols for Bone Marrow Transplant Service 1988 – Present**

**SCHOLARLY SERVICE**

EDITOR

**e-Medicine, Chief Editor, ID Articles, Medscape 2014 –  
present**

**The British Journal of Antimicrobial Chemotherapy 2010 - Present**

**e-Medicine 2000 – 2001,  
2005, 2010 -  
Present**

Indian Journal of Medical Microbiology

EDITORIAL BOARD

**The Open Antimicrobial Agent Journal 2011 - Present**

**GERMS 2009 – Present**

**The Scientific World Journal 2009 – Present**

REVIEWER

Project Outline Application for Swiss National Science Foundation 2000 – 2001

JOURNAL REVIEWER

Antimicrobial Agents and Chemotherapy

Biology of Blood and Marrow Transplantation

Bone Marrow Transplantation

Clinical Infectious Diseases

Journal of Antimicrobial Chemotherapy

JOURNAL REVIEWER (continued)

Archives of Internal Medicine

Cancer

Critical Care Medicine

European Journal of Clinical Infection

Annals of Pharmacotherapy

The National Medical Journal of India

Indian Journal of Medical Microbiology

Drug Intelligence and Clinical Pharmacy

Journal of Respiratory Diseases

Sentinel Reader/McMaster University

Am. Soc. Hematology, Education Program Book

2006

**TEACHING**

Wayne State University

Medical Students

**Regular teaching rounds on the Infectious Diseases Consultation Service**

**1983 – Present**

Physical Diagnosis for second year medical students

1983 – 2010

Residents/Fellows

Hematology/Oncology House Staff – Management of Infections in  
Compromised Hosts - Monthly

1988 – 2011

Residents/Fellows (continued)

**Regular teaching rounds on the Infectious Diseases Consultation Service** 1983 – Present

Faculty

**Wayne State Faculty** 1983 – Present

Mentoring

**Aws Hasan 3<sup>rd</sup> Year Medical Student Continuity Clinic Clerkship** 2014

**Cecily Dubusker 3<sup>rd</sup> Year Medical Student Continuity Clinic Clerkship** 2014

**Saghar Saber 3<sup>rd</sup> Year Medical Student Continuity Clinic Clerkship** 2013

**Sepehr Bhadorani 3<sup>rd</sup> Year Medical Student Continuity Clinic Clerkship** 2013

**Cale Streeter 1<sup>st</sup> Year Medical Student MD/PhD Integrated Clinical Experience** 2013

**Najibah Rehman 3<sup>rd</sup> Year Medical Student Continuity Clinic Clerkship** 2012

**Mentoring Internal Medicine Residents / Infectious Diseases Fellows/  
Medical Students** 1997 – Present

Ph.D. – Microbiology, University of Calcutta, India 1990

Essays/Theses/Dissertations directed

Ph.D. – Thesis review – Promila Mohan Raj, M.D. – ‘Clinico-epidemiologic Study of Anthrax in India’. The Tamilnadu Dr. M.G.R. Medical University, Chennai, India 2009

Ph.D. – Thesis review – Dilip Mathai, M.D. – ‘Clinico-epidemiologic Study of Antimicrobial Resistance in Bacterial Pathogens in Different States of India’. The Tamilnadu Dr. M.G.R. Medical University, Chennai, India 2008

**PRESENTATIONS**

International & National Programs

**2014 China Hematology Anti-Infective Forum/China Continuing Medical Education** 2014  
Press. Beijing, Shanghai and Guangzhou, China, April 10-20.

- Staphylococcal Infections in the Critically Ill
- Gram Positive Infections in the Immunocompromised Patient

**Clinical Infectious Diseases Society of India, 4<sup>th</sup> Annual Conference in Infectious Diseases, Bangalore, India.** 2014

- Infections in Patients on Immunosuppressive Drugs
- Fungal Infections

<b>Meeting, India</b> <ul style="list-style-type: none"><li>• <b>Antifungal Drugs” &amp; “Infections Associated with Biologic Agents</b></li></ul>	<b>2014</b>
<b>American College of Medicine Meeting</b> <ul style="list-style-type: none"><li>• <b>Professors in Action</b></li></ul>	<b>2014</b>
<b>Annual Meeting – Clinical Infectious Diseases Society /India, Mumbai, India.</b> <b>Plenary speaker: “Emerging Infectious Diseases”; Fungal Symposium: Chairman</b>	<b>2013</b>
<b>University of Toronto, Transplant – Infectious Diseases:</b> <b>Recent Development in Management of CMV Infections in Transplantation,</b> <b>Toronto, Ontario Canada</b>	<b>2013</b>
<b>University of London, Ontario Canada: Inf. In Immunocompromised</b> <b>Hosts, London</b>	<b>2013</b>
<b>Fungal Symposia: Istanbul, Turkey</b>	<b>2013</b>
<b>Fungal Symposia: Porto, Portugal</b>	<b>2012</b>
<b>Annual Meeting, Clinical Infectious Diseases Society of India, Chennai</b>	<b>2012</b>
<b>Annual Meeting Sri Lankan College of Microbiology, Plenary Session</b> <b>(Infections in Stem Cell Recipients), Colombo Sri Lanka</b>	<b>2012</b>
Annual Meeting, Clinical Infectious Diseases Society of India, Hyderabad	2011
Symposium: Leukemia and its complications. European Hematology Association, Annual conference, Barcelona, Spain	2010
<b>Symposium on Fungal Infections, Annual Meeting of Infectious diseases Society of America (IDSA)</b>	<b>2009, 2012</b>
26 <sup>th</sup> International Congress of Chemotherapy and Infection (ICC), Toronto - International Advisory Committee	06/2009
Chair, indo-US Infectious Diseases Conference, Chennai, India	08/2008
Invited speaker, National Infection Control Society Meeting, Christian Medical College and Hospital, Vellore, India	01/2003
Chair, Asian American International Medical Society. Advances in Medicine for the New Millennium, Goa, India	01/3-5/2003
Round Table Session – 12 <sup>th</sup> International Symposium – Immunocompromised	1999

Host Society, Bergen, Norway, 2002

Meet-the-Professor Sessions, Annual Meeting of Infectious Diseases Society of America 1999

Coordinator, symposium of Nosocomial Infections, Christian Medical College and Hospital, Vellore, India 1992

Local/regional

**Winter Didactic for 2<sup>nd</sup> Year I.D. Fellows, Harper University Hospital, Detroit 2014**

- **Anatomy of a Scientific Paper**

**BMT Didactic Lecture, Children's Hospital of Michigan, Detroit 2014**

- **Hematology Infections in Stem Cell Patients**

**Infectious Diseases Didactic Lecture, Harper University Hospital, Detroit 2014**

- **Viral Infections in Cancer/Transplant Recipients**

**Physician Assistant Student Lectures, WSU Pharmacy Building, Detroit 2014**

- **Immunocompromised Hosts**

**Infectious Diseases Didactic Lecture, Harper University Hospital, Detroit 2014**

- **Viral Infections in Cancer/Transplant Recipients**

**Infectious Diseases Summer Didactic Lectures, Harper University Hospital, Detroit 2014**

- **Commonly Used Lab Tests**

**Med. Microbiology Course Tutorials Year III Med Students 2014**

**Infectious Diseases Video Conference with Apollo Health System Chennai, India 2014**

**Update in Infectious Diseases, Detroit 2014**

- **Infections Issues Unique to Compromised Hosts**

**Rheumatology Meeting, Detroit Receiving Hospital, Detroit 2014**

- **Infections Associated with Biologic Agents**
- **Infection Issues Unique to Compromised Hosts**
- **Newer Drugs – What Should I Know About Infections?**

**Update In Infectious Diseases, Speaker: Infection in the Compromised Host, Detroit, MI 2013**

**13<sup>th</sup> Annual Update in Internal Medicine/Bay Harbor, MI: Speaker: 2013**

- **Varicella Zoster Management and Prevention**
- **Clostridium difficile Infection**



**GRANTS & CLINICAL TRIALS ACTIVITIES**

<b>Optimer: A Phase 3b Multi-Center, Double-Blind, Safety and Efficacy of Fidaxomicin for Prophylaxis against Clostridium difficile Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation – Principal Investigator</b>	<b>2013</b>
<b>Glaxo-Smith Kline: A Phase III Randomized, Observer-Blind, Placebo- Controlled, Multicenter, Clinical Trial to Assess the Prophylactic Efficacy, Safety, and Immunogenicity of GSK Biological's Herpes Zoster gE/AS01b Candidate Vaccine When Administered Intramuscularly on a Two -Dose Schedule to Adult Autologous Hematopoietic Stem Cell Transplant (HCT) Recipients. - Principal Investigator</b>	<b>2013</b>
<b>Genetech: : A Double-Blind, Randomized, Stratified, Multi-Center Trial Evaluating Conventional and High Dose Oseltamivir in the Treatment of Immunocompromised Patients with influenza – Principal Investigator</b>	<b>2013</b>
<b>Merck: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs) – Principal Investigator</b>	<b>2011 - 2013</b>
<b>Chimerix: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients - Principal Investigator</b>	<b>2010-2013</b>
<b>Merck &amp; Company: A Prospective, Non-Intervention, Observational Assessment of the Correlation Between Circulating Biomarkers of Fungal Bioburden and Clinical Outcome in the Setting of Invasive Aspergillosis - Principal Investigator</b>	<b>2009</b>
<b>Pfizer - \$123,659 – A Prospective Randomized Trial Comparing the Efficacy of Anidulafungin and Voriconazole in Combination to That of Voriconazole Alone When Used for Primary Therapy of Proven or Probable Invasive Aspergillosis Principal Investigator</b>	<b>2008</b>
<b>Schering Plough - \$47,802 – A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole Among Patients with Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infections - Principal Investigator</b>	<b>2008</b>
<b>Vical Inc. - \$45,788 – A Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity and Clinical Benefit of a CMV Immunotherapeutic Vaccine in Donors and Seropositive Recipients Undergoing Allogeneic, Matched Related Hematopoietic Cell Transplant (HCT) -</b>	<b>2006</b>

**GRANTS & CLINICAL TRIALS ACTIVITIES (continued)**

Optimer Pharmaceuticals, Inc. - \$56,070 – A Multinational, Multi-Center, Double-Blind, Randomized, Parallel Group Study to Compare the Safety And Efficacy of 200mg PAR-101 taken q 12 hrs with 125mg Vancomycin Taken q 6 hrs for Ten Days in Subjects with Clostridium Difficile-Associated Diarrhea – Co-Investigator	2006
Schering Plough - \$41,969 – Open-label, Limited Access Protocol of Posaconazole in Invasive Fungal Infection – Co-Investigator	2006
Invasive Fungal Infections-Molecular Diagnosis (Molecular Diagnosis of Pathogenic Fungi 5R03 A162949-P1:R.Akins) Co-Investigator	2005
Michigan Technology Corridor Viropharma Incorporated - \$183,000.00 – A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Safety, Tolerability and Prophylactic Anti-cytomegalovirus Activity of Maribavir in Recipients of Allogeneic Stem Cell Transplant – Co-Investigator	2005
Genome Therapeutics Corporation - \$29,750.00 – A Phase II, Randomized, Open Label, Multicenter Trial of Ramoplanin Versus Vancomycin for the Treatment of Clostridium difficile Associated Diarrhea – Co-Investigator	2003
Enzon Pharmaceuticals - \$130,000 – a) Efficacy of ABLC vs. Voriconazole-Resistant Aspergillus Fumigatus in a Guinea Pig Pulmonary Aspergillosis Model. b) Efficacy of ABLC plus Voriconazole vs. Asp. Fumigatus in a Guinea Pig Pulmonary Aspergillosis Model. c) Efficacy of ABLC Plus Caspofungin vs. Asp. Fumigatus in a Murine Pulmonary Aspergillosis Model.	2003
Schering - \$66,000 – A Randomized Controlled Trial of Posaconazole (SCH 5692) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk neutropenic Patients. Principle Investigator	2003
Fujisawa Study - \$130,000 – (a) Post Antifungal Effect of Micafungin; (b) Efficacy of Micafungin plus Amphotericium B against Aspergillosis in an Animal Model; (c) Molecular Mechanisms of Micafungin Resistance in Aspergillus.	2003
Fujisawa Study - \$32,500 – A Phase II, Open Label, Non-comparative Trial of Micafungin FK 4630 in Combination with AmBisome as Firstline Therapy in the Treatment of Invasive Aspergillosis	2002
Elan Pharmaceuticals - \$12,000 – In vitro Evaluation of Abelcet (ABLC) Alone and in Combination with an Echinocandin Against Aspergillus Fumigatus. Principle Investigator	2001

**GRANTS & CLINICAL TRIALS ACTIVITIES (continued)**

Cubist Pharmaceuticals - \$161,000 – A Randomized, Double-Blind, Double-Dummy, Phase III Comparative Study of Cidecin (Daptomycin) and Zyvox (Linezolid) In the Treatment of Hospital Adults with Suspected Vancomycin-Resistant Enterococcal Infection. Principal Investigator	2001
Pharmacia & Upjohn - \$150,000 – A Randomized, Open-Label Phase IV Clinical Trial Comparing Linezolid IV or PO to Unasyn IV or Augmentin PO for the Treatment of Patients with Diabetic Foot Infections. Principal Investigator	2001
Intrabiotics Pharmaceuticals, Inc - \$120,000 – A Phase III, Randomized Parallel, Placebo-Controlled, Double-Blind, Multicenter Efficacy and Safety Study of Ramoplanin and Placebo in Neutropenic Oncology Patients Identified as Asymptomatic Carriers of Vancomycin-Resistant Enterococcus (VRE). Co-Principal Investigator	2001
Merck & Company, Inc. - \$25,000 – In-vitro Evaluation of Caspofungin Singly and in Combination with Amphotericin B/azoles Against Aspergillus. Principal Investigator	2001
Children’s Research Center of Michigan - \$100,000 – Studies on Antifungal Agents Against Aspergillus – Co-Principal Investigator	2000
Fujisawa Pharmaceuticals - \$25,000 – In-vitro Evaluation of FK 463 Singly and in Combination with Amphotericin B/liposomal Amphotericin B Against Aspergillus Fumigatus – Principal Investigator	2000
Pfizer Pharmaceuticals - \$99,000 – In-vitro and In-vivo (animal model) Activity Of Combination of Antifungal Agents Against Aspergillus fumigatus – Principal Investigator	2000
Fujisawa Pharmaceuticals - \$80,000 – A Phase III, Randomized, Double-Blind, Comparative Trial of FK463 versus Fluconazole for the Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoietic Stem Cell Transplant – Principal Investigator	2000
Schering institute - \$90,000 – A Phase III Randomized, Double-Blind (Double-Dummy) Study of the Safety, Tolerance and Efficacy of SCH 56592 vs. Fluconazole In the Prophylaxis of Invasive Fungal Infections in High-Risk Recipients of Allogeneic Progenitor Cell Transplantation with Graft-Versus-Host-Disease – Principal Investigator	1999
Pfizer Pharmaceuticals - \$116,384 – A Randomized, Open Label, Comparative Multicenter Trial of Voriconazole vs. Ambisome for Empirical Antifungal Therapy in immunocompromised Patients with Persistent Fever and Neutropenia Principal Investigator	1998

**GRANTS & CLINICAL TRIALS ACTIVITIES (continued)**

Pfizer Pharmaceuticals - \$63,425 – An Open Label, Non-comparative, Multicenter Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary Or Secondary Treatment of Invasive Fungal Infections – Principal Investigator	1998
Pfizer Pharmaceuticals - \$63,425 – An Open Randomized Comparative Multicenter Study of the Efficacy, Safety and Toleration of Voriconazole versus Amphotericin B Followed by other Licensed Antifungal Therapy in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients – Principal Investigator	1997
Immunex - \$56,000 – A Phase II/III Randomized, Double-Blind Placebo-Controlled Trial of recombination Human Granulocyte-Macrophage Colony-Stimulating Factor (rhu GM-CSF) Used to Prevent Invasive Fungal Infections in Patients with Graft-Versus-Host-Disease – Principal Investigator	1997
Sequus Pharmaceuticals - \$35,000 – A Double-Blind, Randomized Multicenter of the Safety, Efficacy and Toleration of Three Doses of ABCD (Ampho B Colloidal Dispersion) vs. Amphotericin B in the Treatment Oropharyngeal Candidiasis (OPC) And Esophageal Candidiasis Failing Azole Therapy in AIDS Patients – Principal Investigator	1997
Pfizer Pharmaceuticals - \$78, 303 – Evaluation of Voriconazole Against Pulmonary Aspergillosis in a Guinea Pig Model – Principal Investigator	1997
Pfizer Pharmaceuticals - \$11,853 – In-vitro Susceptibilities of Aspergillus Against Voriconazole, Itraconazole and Amphotericin B – Principal Investigator	1997
Pfizer Pharmaceuticals - \$64,300 – A Multicenter, Randomized, Double-Blind, Active-Controlled Phase I Study to Investigate the Safety, Tolerance and Pharmacokinetics of Three Increasing Oral Doses of Voriconazole in Patients with Hematologic Malignancies/Conditions, Solid Tumors or Autologous Bone Marrow Transplantation at Risk for Aspergillosis – Principal Investigator	1996
Janssen Research Foundation - \$97,500 – A Randomized Trial of Fluconazole versus Itraconazole for the Prevention of Fungal Infections in Allogeneic Bone Marrow Transplant Patients – Principal Investigator	1996
Sequus Pharmaceuticals - \$30,000 – A Double-Blind, Randomized Comparison of ABCD and Fungizone in the Treatment of Febrile neutropenic Patients Failing Antibacterial Therapy – Principal Investigator	1996
Sequus Pharmaceuticals - \$70,000 – A Double-Blind, Randomized Comparison of Amphocil and Fungizone in the Treatment of Invasive Aspergillosis – Principal Investigator	1995

**GRANTS & CLINICAL TRIALS ACTIVITIES (continued)**

Glaxo Wellcome - \$67,415 – An Open-Label Pilot Study to Estimate the Effect on Patient Survival and Safety of CMV Prophylaxis with IV Acyclovir Followed by Valacyclovir Hydrochloride or Ganciclovir in Allogeneic bone Marrow Transplant Recipients – Principal Investigator	1995
Liposome Company, Inc - \$100,657 – A Phase III, randomized Study of Amphotericin B Lipid complex (ABLCL <sup>®</sup> ) vs. Amphotericin B Desoxycholate In the Empiric Treatment for Fungal Infections in Neutropenic Subjects – Principal Investigator	1994
Pharmaco LSR - \$60,000 – Double-Blind, Randomized Trial of Cefepime vs. Ceftazidime for the Empiric Treatment of Febrile Episodes in Neutropenic Cancer Patients Principal Investigator	1993
Food and Drug Administration, Department of Health and Human Services \$141,469- Consultant – Clinical Trial of Zinc in Sickle Cell Anemia	1993
National Institutes of Health Collaborative Antiviral Study - \$70,000 – Evaluation Of SQ 32,756 (BV-ara-U) versus Acyclovir in the Treatment of Localized Herpes Zoster in Immunocompromised Patients – Principal Investigator	1993
Roerig - \$10,000 – Comparative Study of Cefoperazone/Sulbactam versus Cefoperazone in the Treatment of Disseminated Pseudomonas aeruginosa Infection in the Neutropenic Mouse Model – Principal Investigator	1992
Roerig - \$23,839 – Comparative Study of Cefoperazone/Sulbactam versus Cefoperazone in the Treatment of Disseminated E. coli Infection in the Neutropenic Mouse Model – Principal Investigator	1991
Roerig - \$476,208 – Double-Blind Randomized Study of Cefoperazone + Sulbactam Versus Ceftazidime in the Treatment of Febrile, Neutropenic Patients –	1991
Eli Lilly - \$13,499 – Cilofungin in Disseminated Candidiasis: Dose Ranging Study Principal Investigator	1990
Schering - \$23,037 – Comparison of the Safety and Efficacy of SCH 39304 and Ketocanazole in the Treatment of Oropharyngeal Candidiasis in Cancer Patients Principal Investigator	1990
Xoma Corp. - \$46,000 – Double-Blind Randomized Placebo Controlled Group Comparative Study to Determine the Safety and efficacy of Xomen <sup>™</sup> – E5 In Patients with Suspected Gram-Negative Sepsis – Principal Investigator	1989

**GRANTS & CLINICAL TRIALS ACTIVITIES (continued)**

Pfizer Inc. - \$110,000 – Double-Blind Placebo Controlled Study of Fluconazole in the Prevention of Fungal Infections in Neutropenic Patients Undergoing Therapy for Leukemia – Principal Investigator	1989
Pfizer Inc. - \$66,000 – Double-Blind Placebo Controlled Study of Fluconazole in The Prevention of Fungal Infections in Neutropenic Patients Undergoing Therapy for Bone Marrow Transplantation – Principal Investigator	1989
Pfizer Inc - \$105,155 – A Randomized Comparative Multicenter Trial of Fluconazole and Ketoconazole in the Treatment of Esophageal Candidiasis in Immunocompromised Patients – Principal Investigator	1988
Roerig - \$10,000 – Evaluation of Cefoperazone/Sulbactam, Other Betalactams, Aminoglycoside & Quinolones Against Multi-Resistant Gram-Negative Rods Principal Investigator	1988
Beecham Laboratories - \$12,000 – In-vitro Evaluation of Betalactamase Inhibition Of Methicillin Resistant Staphylococcus Aureus & Staphylococcus Epidermidis Principal Investigator	1988
Xoma Corporation - \$40,000 – Safety & Efficacy of Antiendotoxin Antibody XOMEN-E5 in the Treatment of Patients with Suspected Gram-Negative Bacteremia or Endotoxemia – Principal Investigator	1987
Merrell Dow Research Institute - \$116,049.93 – An Open Study of Teicoplanin in the Treatment of Intravenous Drug Abuse Associated Endocarditis/Bacteremia Caused By Gram-Positive Bacteremia – Principal Investigator	1987
Merrell Dow Research Institute - \$ 118,512 – A Randomized Blinded Comparative Study of Teicoplanin versus Vancomycin in the Treatment of Non-Vascular Access Associated Bacteremia/Endocarditis Caused by Gram-Positive Bacteria Principal Investigator	1987
Eli Lilly - \$23,942 – Efficacy of Endotracheal Instillation of Tobramycin in the Treatment of Gram-Negative Pneumonia – Principal Investigator	1986
Merck Sharp & Dohme – 9,400 – Efficacy in Imipenem/Cilastatin in the Treatment of methicillin-Resistant Staphylococcus Aureus Endocarditis in the Rabbit Model – Principal Investigator	1985
Harper Hospital Medical Staff Trust Fund - \$11,800 – High Prevalence of Piperacillin Resistant E. coli: elucidation of Mechanisms and Probable Cure – Principal Investigator	1984

### **GRANTS & CLINICAL TRIALS ACTIVITIES (continued)**

Lederle - \$5,000 – Plasmid Analysis of Piperacillin Resistant E. coli and Possible Transfer to P. aeruginosa – Principal Investigator	1984
Roche - \$3,700 – Therapy with Newer Agents (Including Coumermycin) in the Treatment of Methicillin resistant Staphylococcus aureus Endocarditis in the Rabbit Model – Principal Investigator	1984
Lederle - \$7,260 – Usefulness of Prophylactic Piperacillin Therapy During ERCP Principal Investigator	1984

### **PUBLICATIONS**

#### Original Observations in Refereed Journals

1. **Bhargava A, Chandrasekar PH. Gradually Worsening Tattoo Lesion. JAMA Clinical Challenge 314:19:2071-2072 2015**
2. **Chandrasekar PH, Havlichek D, Johnson LB. Infectious Diseases Subspecialty: Declining Demand Challenges and Opportunities. Clin Inf Disease. 59:1593-8, 2014.**
3. **Duarte R, Lopez-Jimenez J, Cornely O, Laverdiere M, Haider S, Chandrasekar PH, Langston A, Perfect J, Ma L, van Iersel M, Connelly N, Kartsonis N, Waskin H. Phase 1b Study of New Posaconazole Tablet for the Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia. Antimicrob Agents Chemother 58:5758-65, 2014.**
4. **Salimnia H, Fairfax MR, Chandrasekar PH. Detection and Pharmacokinetics of a Cytomegalovirus (CMV) DNA Plasmid in Human Plasma During a Clinical Trial of an Intramuscular CMV Vaccine in Hematopoietic Stem Cell Transplant Recipients. Transpl Infect Dis 16:914-8, 2014.**
5. **Gupta N, Rodrigues C, Shetty A, Gursahani R, Ashok PP, Chandrasekar PH, Soman R. Case Series-Diabetes Associated Invasive Mucormycosis of Skull Base. Ann Geriatr Educ & Med Sciences, Jan-June, Volume 1 Issue 1 pp 1-4, 2014.**
6. **Revankar SG, Moudgal V, Chandrasekar P, Sobel JD. In Vitro Studies of Exserohilum rostratum with Antifungal Drugs and Methylprednisolone. Antimicrob. Agents Chemother 58:3564-5, 2014.**
7. **Vergidis P, Razonable JJ, Wheat LJ, Estes L, Caliendo AM, Baden L, Wingard JR, Baddley J, Assi M, Norris S, Chandrasekar PH, Shields R, Nguyen H, Freifeld A, Kohler R, Kleiman M, Walsh TJ, Hage CA. Reduction in false-positive Aspergillus serum galactomannan results associated with the use of piperacillin-tazobactam in the United States. Journal of Clinical Microbiology. 52:2199-201, 2014.**

Original Observations in Refereed Journals (continued)

8. Patel D, Marchaim D, Marcus G, Gayathri R, Lephart PR, Lazarovitch T, Zaidenstein R, Chandrasekar PH. Predictors and outcomes of acyclovir-resistant herpes simplex virus infection among hematopoietic cell transplant recipients: case-control investigation. *Clin Transplant* 28:1-5, 2014.
9. Ramesh MS, Chandrasekar PH. Invasive Aspergillosis. *BMJ Point-of-Care*, 2009; [www.pointofcare.bmj.com](http://www.pointofcare.bmj.com) (Updated 2014)
10. Lerchenfeldt S, Chandrasekar PH. A Pilot Study on the Effect of Vaccination Cards and Telephone Outreach on Vaccination Adherence in Hematopoietic Stem Cell Transplant (HSCT) patients. *Transpl Infect Dis* 15:634-8, 2013.
11. Krishnan-Natesan S, Wu W, Cutright JL, Chandrasekar PH. In vitro Efficacy of the Combination of Voriconazole and Anidulafungin against Voriconazole-Resistant Cyp51A Mutants of *Aspergillus fumigatus*. *Diagnostic Microbiology and Infectious Disease* 73:135-137, 2012.
12. Krishnan-Natesan S, WU W, Cutright JL, Chandrasekar PH. In vitro – In vivo Correlation of Voriconazole Resistance due to G448S Mutation (cyp51A gene) in *Aspergillus fumigatus*. *Diagnostic Microbiology and Infectious Disease* 74:272-277, 2012.
13. Ramesh MS, Chandrasekar PH. Invasive Aspergillosis. *BMJ Point-of-Care*, 2009; [www.pointofcare.bmj.com](http://www.pointofcare.bmj.com) (November 1, 2012)
14. Chin L, Schiffer C, Chandrasekar PH, Masood A. Adherence to Hepatitis B Screening and Prophylactic Lamivudine for Prevention of Rituximab-Associated Hepatitis B Reactivation. *J Oncol Pharm Pract*, 19:18-23, 2013.
15. Hayakawa K, Ramasamy B, Chandrasekar PH. Fever of Unknown Origin: An Evidence-Based Review. *Am J Med Sciences*, 344:307-16, 2012
16. Miceli MH, Chandrasekar PH. Safety and Efficacy of Liposomal Amphotericin B for the Empirical Therapy of Invasive Fungal Infections in Immunocompromised Patients. *Infection and Drug Resistance*, 5:9-16, 2012
17. Bharadwaj R, Swaminathan S, Salimnia H, Fairfax M, Frey A, Chandrasekar PH. Clinical Impact of the Use of 16S rRNA Sequencing Method for the Identification of Difficult-to-Identify Bacteria in Immunocompromised Hosts. *Transpl Infect Dis*, 14:206-12, 2012
18. Miceli M, Cronin S, Ayash L, Alangaden G, Chandrasekar PH. Significant Interaction of Tacrolimus and Ritonavir During Allogeneic Hematopoietic Stem Cell Transplantation in a HIV Infected Patient. *BMT*, 47:1140-142, 2011



Original Observations in Refereed Journals (continued)

19. Chandrasekar PH. Urgent Need for Formal Medical Training in Infectious Diseases in India. *Lancet Infectious Diseases*, 11:809-10, 2011
20. Kosmidis CI, Chandrasekar PH. Management of Gram-positive Bacterial Infections in Cancer Patients. *Leuk Lymphoma*, Jan 2012, 53:8-18, 2011
21. Chandrasekar PH. The Management of Invasive Fungal Infections: A Role for Polyenes. *JAC*, 66:457-465, 2011
22. Chopra T, Chandrasekar PH, Salimnia H, Heilbrun L, Smith D, Alangaden GJ. Epidemiology of *Clostridium difficile* Infection in Hematopoietic Stem Cell Transplant Recipients. *Clin Transplant*, 25:E82-E87, 2011
23. Mehtra T, McGrath E, Bheemreddy S, Salimnia H, Abdel-Haq N, Ang JY, Lum L, Chandrasekar PH, Alangaden GJ. Detection of Oseltamivir Resistance During Treatment of 2009 H1N1 Influenza Virus Infection in Immunocompromised Patients: Utility of Cycle Threshold Values of Qualitative Real-Time Reverse Transcriptase PCR. *J Clin Microbiol*, 11:4326-4328, 2010
24. Chopra T, Alangaden GJ, Chandrasekar PH. *Clostridium difficile* Infection (CDI) in Cancer Patients and Hematopoietic Stem Cell Transplant Recipients. *Expert Rev Anti Infect. Ther*, 8:1113-1119, 2010
25. Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, Mattiuzzi GN, Chandrasekar PH, Kontoyiannis DP, Rolston KV, Walsh TJ, Champlin RE, Raad II. A Review and Meta-Analysis of Drug-Induced Nephrotoxicity Caused by Amphotericin B Lipid Complex and Liposomal Amphotericin B. *Medicine (Baltimore)*, 89:236-44, 2010
26. Krishnan-Natesan S, Manavathu EK, Cutright J, Chandrasekar PH. Efficacy of Anidulafungin, Caspofungin and Fluconazole in the Early Phase of Infection in a Neutropenic Murine Invasive Candidiasis Model. *Int J Antimicrob Agent*, 36:33-6, 2010
27. Chandrasekar PH. Prophylaxis Versus a Preemptive Approach for Invasive Aspergillosis. *Current Fungal Infection Reports*, 4:30-37, 2010
28. Chandrasekar PH. Diagnostic Challenges and Recent Advances in the Early Management of Invasive Fungal Infections. *Eur J Hematology*, 84:281-90, 2010
29. Wahby K, Chopra T, Chandrasekar PH. Intravenous/Inhalational Colistin-Induced Respiratory Failure. *Clin Infec Dis*, 50:e38-40, 2010
30. Cronin S, Chandrasekar PH. Safety of Triazole Anti-Fungal Drugs in Patients with Cancer. *J Antimicrob Chemother*, 65:410-6, 2010
31. Ramesh MS, Chandrasekar PH. Invasive Aspergillosis. *BMJ Point-of-Care*, 2009; [www.pointofcare.bmj.com](http://www.pointofcare.bmj.com) (November 1, 2009)

Original Observations in Refereed Journals (continued)

32. Ramesh MS, **Chandrasekar PH**. Challenges in the Management of Invasive Aspergillosis in Hematopoietic Stem Cell Transplantation (HSCT). Expert Review of Anti-Infective Therapy, 7:115-3, 2009
33. Krishnan-Natesan S, **Chandrasekar PH**. A comparison of the Fungicidal Activity of Amphotericin B and Posaconazole Against Zygomycetes In-vitro. Diagn Microbiol Infect Dis, 63:361-4, 2009
34. Nailor M, **Chandrasekar PH**. Treatment of Breakthrough Fungal Infections: Is There One Best Drug Strategy? Current Fungal Infection Reports, 3:229-235, 2009.
35. Nailor M, **Chandrasekar PH**. Antifungal Drugs: Predicting Clinical Efficacy with Pharmacodynamics. Expert Rev Clin Pharmacol, 2:373-379, 2009
36. **Chandrasekar PH**. Invasive Mold Infections; Recent Advances in Management Approaches. Leukemia & Lymphoma, 50: 703-715, 2009
37. Krishnan-Natesan S, Manavathu EK, **Chandrasekar PH**. Aspergillus flavus: The Emerging Non-Fumigatus Aspergillus Species of Significance and a Review of the Literature. Mycoses, 52:206-22, 2009
38. **Chandrasekar PH**, Bharadwaj RA, Polenakovik H, Polenakovik S. Strongyloidiasis. eMedicine from WebMD. Updated April 30, 2009. Available at: <http://emedicine.medscape.com/article/229312-overview>
39. Liu PF, Euerle B, **Chandrasekar PH**. Syphilis. eMedicine from WebMD. Updated February 4, 2009. Available at: <http://www.emedicine.com/med/topic2224.htm>
40. Ramesh MS, **Chandrasekar PH**. Effective Alternates to Trimethoprim-Sulfamethoxazole as Antimicrobial Prophylaxis in Stem Cell Recipients: Are There Any? Pediatric Transplantation, 12:823-6, 2008
41. Krishnan-Natesan S, **Chandrasekar PH**, Alangaden GJ, Manavathu EK. Molecular Characterization of cyp51A and cyp51B Genes Coding for P450 14 Alpha-Lanosterol Demethylase A (CYP15Ap) and B (CYP51Bp) from Voriconazole-Resistant Laboratory Isolates of Aspergillus Flavus. Int J Antimicrob Agents, 32:519-524, 2008
42. Krishnan-Natesan S, **Chandrasekar PH**, Manavathu EK, Revankar SG. Successful Treatment of Primary Cutaneous Aspergillus ustus Infection with Surgical Debridement and a Combination of Voriconazole and Terbinafine. Diagn Microbiol Infect Dis, 62:443-446, 2008
43. **Chandrasekar PH**. Prophylaxis Against Aspergillus is not Perfect: Problems and Perils in Stem Cell Transplantation. Med Mycol, 29:1-6, 2008

Original Observations in Refereed Journals (continued)

44. **Chandrasekar PH.** Amphotericin B Lipid Complex: Treatment of Invasive Fungal Infections in Patients Refractory to Intolerant of Amphotericin B Deoxycholate. *Therapeutics and Clinical Risk Management*, 4:1285-1294, 2008
45. Gruber SA, Doshi MD, Cincotta E, Brown KL, Singh A, Morawski K, Alangaden G, **Chandrasekar PH**, Losanoff JE, West MS, El-Amm JM. Preliminary Experience with Renal Transplantation in HIV + Recipients: Low Acute Rejection and Infection Rates. *Transplantation* 86:269-274, 2008
46. **Chandrasekar PH**, Manavathu EK. Do Aspergillus Species Produce Biofilm? *Future Microbiol* 3:19-21, 2008
47. **Chandrasekar PH**, Ljungman PT. Antifungal Therapy Strategies in Hematopoietic Stem Cell Transplant Recipients: Early Treatment Options for Improving Outcomes. *Transplantation* 86:183-191, 2008
48. Krishnan S, **Chandrasekar PH.** Current and Future Therapeutic Options in the Management of Invasive Aspergillosis. *Drugs* 68:265-282, 2008
49. Natesan SK, **Chandrasekar PH**, Alangaden GJ, Manavathu EK. Fluvastatin Potentiates the Activity of Caspofungin Against Aspergillus Fumigatus In-vitro. *Diagn Microbiol Infect Dis*, 60:369-373, 2008
50. Krishna G, Martinho M, **Chandrasekar PH**, Ullmann AJ, Patino H. Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-Versus-Host Diseases. *Pharmacotherapy*, 27:1627-36, 2007
51. Haririan A, Morawski K, West MS, El-Amm JM, Doshi MD, Cincotta E, Alangaden GJ, **Chandrasekar PH**, Gruber SA. Sirolimus Exposure During the Early Post-Transplant Period Reduces the Risk of CMV Infection Relative to Tacrolimus in Renal Allograft Recipients. *Clin Transplant*, 21:466-471, 2007
52. Afonso NM, Gunasena S, Galla K, Podzorski R, **Chandrasekar PH**, Alangaden GJ. Appropriate Use of Polymerase Chain Reaction for Detection of Herpes Simplex Virus 2 in Cerebrospinal Fluid of Patients at an Inner-City Hospital. *Diagn Microbiol Infect Dis*, 57:309-13, 2007
53. **Chandrasekar PH.** Increased Dose of Echinocandin for Invasive Fungal Infections Bonanza for the Patient or the Pharmaceutical Industry? *Bone Marrow Transplant*, 39:129-131, 2007
54. Ullmann AJ, Lipton JH, Vesole D, **Chandrasekar PH**, Langston A, Tarontolo SR, et al. Posaconazole Versus Fluconazole for Prophylaxis in Graf-Versus-Host Disease. *N Engl J Med*, 356:335-347, 2007

Original Observations in Refereed Journals (continued)

55. Walsh TJ, Raad I, Patterson TF, **Chandrasekar PH**, Donowitz GR, Graybill R, Greene RE, et al. Treatment of Invasive Aspergillosis with Posaconazole in Patients Who are Refractory to or Intolerant of Conventional Therapy: Ext Controlled Trial. *Clin Infect Dis*, 44:2-12, 2007
56. Narreddy S, Mellon-Reppen S, Abidi MH, Klein JL, Peres E, Heilbrun L, Smith D, Alangaden GJ, **Chandrasekar PH**. Non-Bacterial Infections in Allogeneic Non-Myeloablative Stem Cell Transplant Recipients. *Transpl Infect Dis*, 9:3-10, 2007
57. **Chandrasekar PH**. Early Use of Polyenes in Systemic Fungal Infections. *Inf Medicine*, 23:3-11, 2006.
58. Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, Casadevall A, **Chandrasekar PH**, et al. Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. *Clin Infect Dis*, 43:1031-9, 2006.
59. **Chandrasekar PH**. Selection Criteria for Antifungals: The Right Patients and the Right Reasons. *Int J Antimicrob Agents*, 27; Suppl 1:17-20, 2006
60. **Chandrasekar PH**. The Experience is CLEAR: *Int J Antimicrob Agents*, 27; Suppl 1:31-5, 2006
61. Alangaden GJ, Thyagarajan R, Gruber SA, Morawski K, Garnick J, El-Amm JM, West MS, Sillix DH, **Chandrasekar PH**, Haririan A. Infectious Complications After Kidney Transplantation: Current Epidemiology and Associated Risk Factors. *Clin Transplant*, 20;401-9, 2006
62. **Chandrasekar PH**, Sobel J. Micafungin: A New Echinocandin. *Clin Infect Dis*, 42:117177-8, 2006
63. **Chandrasekar PH**, Ito JL. Amphotericin B Lipid complex in the Management of Invasive Aspergillosis in Immunocompromised Patients. *Clin Infect Dis*, 40 Suppl 6:S392-400, 2005
64. **Chandrasekar PH**. Antifungal Resistance in Aspergillus. *Med Mycol*, 43 Suppl 1:S295-8, Review, 2005
65. Ito JI, **Chandrasekar PH**, Hooshmand-Rad R. Effectiveness of Amphotericin B Lipid Complex (ABLC) Treatment in Allogeneic Hematopoietic Cell Transplant (HCT) Recipients with Invasive Aspergillosis (IA). *Bone Marrow Transplant*, 36:873-7, 2005
66. Krishnan S, Manavathu EK, **Chandrasekar PH**. A Comparative Study of Fungicidal Activities of Voriconazole and Amphotericin B Against Hyphae of Aspergillus Fumigatus. *J Antimicrob Chemother*, 55:914-920, 2005

Original Observations in Refereed Journals (continued)

67. **Chandrasekar PH**, Ito JI. Amphotericin B Lipid Complex in the Management of Invasive Aspergillosis in Immunocompromised Patients: Analysis of the CLEAR<sup>®</sup> Database. *Clin Infect Dis*, 40; Suppl 6:S392-400, 2005
68. Gruber SA, Garnick J, Morawski K, Sillix DH, West MS, Granger DK, El-Amm JM, Alangaden GJ, **Chandrasekar PH**, Haririan A. Cytomegalovirus Prophylaxis with Valganciclovir in African-American Renal Allograft Recipients Based on Donor/Recipient Serostatus. *Clin Transplantation*, 19;273-278, 2005
69. **Chandrasekar PH**. Real Time PCR for Early Detection of Toxoplasmosis in Hematopoietic Stem Cell Recipients. Ready for Prime Time? *Clin Infect Dis*, 40:79-81, 2005
70. **Chandrasekar PH**. Riches Usher Dilemmas – Antifungal Therapy in Invasive Aspergillosis. *Biol Blood Marrow Transplant*, 11;77-84, 2005
71. **Chandrasekar PH**. Antifungal Resistance in *Aspergillus*. *Medical Mycology*, 43 (Suppl 1) S295-S298, 2005
72. Manavathu EK, Cutright JL, **Chandrasekar PH**. In-vivo Resistance of a Laboratory-Selected *Aspergillus fumigatus* Isolate to Amphotericin B. *Antimicrob Agents Chemother*, 49;428-430, 2005
73. **Chandrasekar PH**, Cutright JL, Manavathu EK. Efficacy of Voriconazole Plus Amphotericin B/Micafungin in a Guinea Pig Model of Invasive Pulmonary Aspergillosis. *Clinical Microbiology and Infection*, 10:925-928, 2004
74. Wadei H, Alangaden GJ, Sillix DH, El-Amm JM, Gruber S, West MS, Granger DK, Garnick J, **Chandrasekar PH**, Migdal SD, Haririan A. West Nile virus Encephalitis: An Emerging Disease in Renal Transplant Recipients. *Clin Transpl*, 18:753-758, 2004
75. Ganesan LT, Manavathu EK, Cutright JL, Alangaden GJ, **Chandrasekar PH**. In-vitro Activity of Nikkomycin Z Alone and in Combination with Polyenes, Triazoles or Echinocandins Against *Aspergillus fumigatus*. *Clin. Microbiol Infection*, 10:961-966, 2004
76. Alangaden GJ, Brown W, **Chandrasekar PH**. Recognition of Misdiagnosed Tuberculosis in a BMT Recipient Leads to Identification of “Pseudo-tuberculosis” Due to Laboratory Contamination. *Inf Dis Clin Practice*, 12:328-333, 2004
77. Varanasi NL, Baskaran I, Alangaden GJ, **Chandrasekar PH**, Manavathu EK. Novel Effect of Voriconazole on Conidiation of *Aspergillus* Species. *Int J Antimicrob Agents*, 23:72-79, 2004
78. Manavathu EK, Ramesh MS, Baskaran I, Ganesan LT, **Chandrasekar PH**. A Comparative Study of the Post Antifungal Effect (PAFE) of Amphotericin B, Triazoles, and Echinocandins on *Aspergillus fumigatus* and *Candida albicans*. *J Antimicrob Chemother*, 53:386-389, 2004

Original Observations in Refereed Journals (continued)

79. **Chandrasekar PH.** Transplante Autologo De Precursores Hematopoyeticos En El Ambito De La Medicina Ambulatoria. [www.siiclude.com](http://www.siiclude.com) , 2003
80. **Chandrasekar PH.** Autologous Stem Cell Transplantation in the Outpatient Setting: Feasible or Not? <http://www.siicsalud.com/dato/dat031/03203000.htm> , June 2003
81. Winston DJ, Maziarz RT, **Chandrasekar PH**, Lazarus HM, et al. A Multicenter Randomized Trial of Intravenous Itraconazole vs. IV/PO Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients. *Ann Intern Med*, 138:705-713, 2003
82. Winston DJ, Yeager AM, **Chandrasekar PH**, Snyderman DR, et al. Randomized Comparison of Oral Valacyclovir and Intravenous Ganciclovir for Prevention of Cytomegalovirus Disease After Allogeneic bone Marrow Transplantation. *Clin Infect Dis*, 36:749-758, 2003
83. **Chandrasekar PH**, Manavathu EK, Caspofungin. *Drug of Today*, 38:829-846, 2002
84. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Ostemann JW, Kern WB, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, **Chandrasekar PH**, Hodges MR, Schlamm HT, Troke PF, De Pauw B, for Invasive Fungal Infection Group of the European Organization for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus Amphotericin B for Primary Therapy for Invasive Aspergillosis. *New Engl J Med*, 347:408-415, 2002
85. Alangaden GJ, Wahiduzzaman M, **Chandrasekar PH**, and the BMT Group. Aspergillosis: Most Common Serious community Acquired Pneumonia in Allogeneic Stem Cell Transplant Recipients with Graft-Versus-Host Disease. Significance of Gram-negative Bacilli as Co-pathogens. *Clin Infect Dis*, 35:659-664, 2002
86. Pulimood S, Ganesan L, Alangaden GJ, **Chandrasekar PH**. Polymicrobial candidemia. *Diagn Microbiol Infect Dis*, 44:353-353, 2002
87. Bowden R, **Chandrasekar PH**, White MH, Li X, Pietrilli L, Gurwith M, Van Burik J, Laverdiere M, Safrin S, Wingard JR. A Double-Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion (ABCD) vs. Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients. *Clin Infect Dis* 35:359-366, 2002
88. Soubani AO, **Chandrasekar PH**. The Clinical Spectrum of Pulmonary Aspergillosis. *Chest*, 121:1988-1999, 2002
89. Moosa MYS, Alangaden GJ, Manavathu EK, **Chandrasekar PH**. Resistance of Amphotericin B Dose Not Emerge During Treatment for Invasive Aspergillosis. *J Antimicrob Chemother*, 49:209-213, 2002

Original Observations in Refereed Journals (continued)

90. **Chandrasekar PH**, Cutright JL, Manavathu EK. Aspergillus: Rising Frequency of Clinical Isolation and Continued Susceptibility to Antifungal Agents, 1994 – 1999. *Diagn Microbiol Infect Dis*, 41:211-214, 2001
91. **Chandrasekar PH**, Manavathu EK. Voriconazole: A Second Generation Triazole. *Drugs of Today*, 37:135-148, 2001
92. Manavathu EK, Dimmock JR, Vashishtha SC, **Chandrasekar PH**. Inhibition of H<sup>+</sup> - ATPase Mediated Proton Pumping in *Cryptococcus neoformans* by a Novel Conjugated Styryl Ketone. *Journal of antimicrobial Chemotherapy*, 47:491-494, 2001
93. **Chandrasekar PH**, Abraham OC, Klein J, Alangaden GJ, Chalasani G, Cassells L, Dansey R, Abella S, Karanes C, Peters W, Baynes R. Low Infectious Morbidity Following Intensive Chemotherapy and Autologous Peripheral Blood Progenitor Cell transplantation in the Outpatient Setting for Women with Breast Cancer. *Clinical Infectious Diseases*, 32:546-551, 2000
94. Bhargava P, **Chandrasekar PH**. Serious Fungal Infections: Review. *Hospital Physician*, 37:27-28, 2001
95. Kanno M, **Chandrasekar PH**, Bentley G, Vander Heide RS, Alangaden GJ. Disseminated Cytomegalovirus Disease in Non-Conventional Hosts (Non-AIDS/Non-Transplant Patients). *Clinical Infectious Diseases*, 32:313-316, 2001
96. Prasad AS, Fitzgerald JT, Bao B, Beck FWJ, **Chandrasekar PH**. Duration of Symptoms and Plasma Cytokine Levels in Patients with the Common Cold Treated with Zinc Acetate. *Annals of Internal Medicine*, 133:245-252, 2000
97. **Chandrasekar PH**, Arnow PM, Cefepime Versus Ceftazidime as Empiric Therapy for Fever in Neutropenic Patients with Cancer. *Annals of Pharmacotherapy*, 34:989-995, 2000
98. Manavathu EK, Cutright JL, **Chandrasekar PH**. A Comparative Study of the In-Vitro susceptibilities of Clinical Laboratory-Selected Resistant Isolates of *Aspergillus* Species to Amphotericin B, Itraconazole, Voriconazole and SCH 56592. *Journal of Antimicrobial Chemotherapy*, 46:229-234, 2000
99. McNeil SA, Clark NM, **Chandrasekar PH**, Kauffman CA. Successful Treatment of Vancomycin-Resistant *Enterococcus Faecium* Bacteremia with Linezolid After Failure of Treatment with Synercid (Quinupristin/Dalfopristin). *Clinical Infectious Diseases*, 30:403-404, 2000
100. Samuel J, Alangaden GJ, **Chandrasekar PH**. Cervical Adenitis Due to Mycobacterium Fortuitum in a Patient with AIDS. *Infectious Diseases in Clinical Practice*, 9:221-222, 2000

Original Observations in Refereed Journals (continued)

101. **Chandrasekar P H**, Cutright JL, Manavathu EK, Efficacy of Voriconazole Against Invasive Pulmonary Aspergillosis in a Guinea Pig Model. *The Journal of Antimicrobial Chemotherapy*, 45:673-676, 2000
102. **Chandrasekar PH**. Management of Fever in Neutropenic Cancer Patients: Review. *Hospital Physician*, February 2000, 37-38
103. **Chandrasekar PH**, Alangaden GJ, Manavathu EK. Aspergillus – A Rising Problem in Tertiary Care Hospital. *Clinical Infectious Diseases*, 30:984, 2000
104. Manavathu EK, Nune U, Kanuri K, **Chandrasekar PH**, Abraham OC. Effect of Test Medium on the In-Vitro Susceptibility Testing Results for *Aspergillus fumigatus*. *Rev Iberoam Micol*, 17:107-110, 2000
105. Manavathu EK, Dimmock JR, Vashishtha SC, **Chandrasekar PH**. Proton Pumping ATPase Targeted Antifungal Activity of a Novel Conjugated Styryl Ketone. *Antimicrobial Agents and Chemotherapy*, 43:2950-2050, 1999
106. Prasad AS, Beck FWJ, Kaplan J, **Chandrasekar PH**, Ortega J, Fitzgerald JT, Swerdlow P. Effect of Zinc Supplementation on Incidence of Infections and Hospital Admissions in Sickle Cell Disease (SCD). *American Journal of Hematology*, 61:194-202, 1999
107. Abraham OC, **Chandrasekar PH**. Emergence of Antimicrobial-Resistant Infections in Cancer Patients. *Indian Journal of Medical Microbiology*, 16:4:143, 1998
108. Ebright JR, **Chandrasekar PH**, Marks S, Fairfax MR, Aneziokoro A, McGinnis MR. Invasive Sinusitis and Cerebritis Due to *Curvularia clavata* in an Immunocompetent Adult. *Clinical Infectious Diseases*, 28:687-689, 1999
109. Manavathu EK, Cutright JL, **Chandrasekar PH**. A Comparative Study of the Susceptibility of Germinated and Ungerminated Conidia of *Aspergillus Fumigatus* to Various Antifungal Agents. *Journal of Clinical Microbiology*, 27:858-861, 1999
110. Manavathu EK, Vazquez JA, **Chandrasekar PH**. Reduced Susceptibility of *Aspergillus fumigatus* to Itraconazole Due to Decreased Intracellular Accumulation of the Antifungal Agent. *International Journal of Antimicrobial Agents*, 12:213-219, 1999
111. Abraham OC, Manavathu EK, Cutright JL, **Chandrasekar PH**. In-vitro Susceptibilities of Aspergillus Species to Voriconazole, itraconazole and Amphotericin-B. *Diag Microbiol Infect Dis*, 33:7-11, 1999
112. **Chandrasekar PH**. Treating Herpes Infections. *Advances in Wound Care*, 12:254-262, 1999



Original Observations in Refereed Journals (continued)

113. Manavathu EK, Cutright, **Chandrasekar PH**. Organism-Dependent Fungicidal Activity of Azoles. *Antimicrob Agents Chemother*, 42:2018-3021, 1998
114. Manavathu EK, Dimmock JR, Vashishtha SC, Cutright JL, **Chandrasekar PH**. In-vitro and In-vivo Susceptibilities of *Aspergillus fumigatus* to a Novel Conjugated Styryl Ketone. *Journal of Antimicrobial Chemotherapy*, 42:585-590, 1998
115. Manavathu EK, Alangaden GJ, **Chandrasekar PH**. In-vitro Isolation and Antifungal Susceptibility of Amphotericin B Resistant Mutants of *Aspergillus fumigatus*. *Journal of Antimicrobial Chemotherapy*, 41:615-619, 1998
116. **Chandrasekar PH**. Safety and Efficacy of Cefoperazone Plus Sulbactam Vs. Ceftazidime in the Empiric Treatment of Febrile Neutropenia. *Journal of Pharmacy Technology*, 14:63-69, 1998
117. **Chandrasekar PH**, Momin F, and BMT Team. Disseminated Toxoplasmosis in Bone Marrow Transplantation (BMT). *Bone Marrow Transplantation*, (19)7:685-689, 1997
118. **Chandrasekar PH**, Fairfax M, Nandi P, Crane L. Cutaneous Infections Due to *Acanthamoeba* in Patients with AIDS. *Archives of Internal Medicine*, 157:567-572, 1997
119. **Chandrasekar PH**, Alangaden GJ. Newer Betalactam Antibiotics. In *Current Opinion in Infectious Diseases*, Ed. Bodey GP, 9:391-397, 1996
120. Ducharme MP, Slaughter R L, Warbasse LH, **Chandrasekar PH**, Van de Velde V, Mannens G, Edwards DJ. Itraconazole and Hydroxy-Itraconazole Serum Concentrations are Reduced More Than Ten-Fold by Phenytoin. *Clinical Pharmacology and Therapeutics*, 58:617-624, 1995
121. **Chandrasekar PH**, Weinmann AJ, Shearer C, and Bone Marrow Transplantation Team. Autopsy-Identified Infections Among Bone Marrow Transplant Recipients. A Clinico-Pathologic Study of 56 Patients. *Bone Marrow Transplantation*, 16:675-681, 1995
122. Vazquez JA, Lundstrom TS, Dembry LM, **Chandrasekar PH**, Boikov D, Perri MB, Zervos MJ. Invasive *Candida guilliermondii* Infection: Case Report, In-Vitro Susceptibility Studies, and Molecular Analysis. *Bone Marrow Transplantation*, 16:849-853, 1995
123. Naik H, Siddique, N, **Chandrasekar PH**. Foscarnet Therapy for Acyclovir-Resistant Herpes simplex Virus-1 Infection in Allogeneic Bone Marrow Transplantation Recipients. *Clinical Infectious Diseases*, 21:1514-1515, 1995
124. Momin F, **Chandrasekar PH**. Antimicrobial Prophylaxis in Bone Marrow Transplantation. *Annals of Internal Medicine*, 123:205-215, 1995
125. Shearer C, **Chandrasekar PH**, Bone Marrow Transplantation Team. Pulmonary Nocardiosis in a BMT Patient. *Bone Marrow Transplantation*, 15:479-481, 1995

Original Observations in Refereed Journals (continued)

126. Alangaden G, **Chandrasekar PH**, Bailey E, Khaliq Y, Bone Marrow Transplantation Team. Antifungal Prophylaxis with Fluconazole During Bone Marrow Transplantation. *Bone Marrow Transplantation*, 14:919-924, 1994
127. **Chandrasekar PH**, Gatny C M, Bone Marrow Transplantation Team. The Effect of Fluconazole Prophylaxis on Fungal Colonization in neutropenic Cancer Patients. *J Antimicrob Chemother*, 33:309-318, 1994
128. **Chandrasekar PH**, Brown WJ. Clinical Issues of Blood Cultures. *Archives of Internal Medicine*, 154:841-849, 1994
129. Gajewski LK, Bailey EM, Brown P, **Chandrasekar PH**. Determination of the Need for a Prospective DUE of Intravenous Immune Globulin at the Detroit Medical Center. *American Society Hospital Pharmacists*, 51:801-805, 1994
130. **Chandrasekar PH**, Gatny CM, Bone Marrow Transplantation Team. Effect of Fluconazole Prophylaxis on Fever and Use of Amphotericin in Neutropenic Cancer Patients. *chemotherapy*, 40:136-143, 1994
131. **Chandrasekar PH**, Sluchak JA, Kruse JA. Therapy with Cefoperazone Plus Sulbactam against Disseminated Infection Due to Cefoperazone-Resistant *Pseudomonas Aeruginosa* and *Escherichia coli* in Granulocytopenic Mice. *Antimicrobial Agents and Chemotherapy*, 37:1927-1930, 1993
132. Shearer C, **Chandrasekar PH**. Cutaneous Alternariosis and Regional Lymphadenitis During Allogeneic Bone Marrow Transplantation. *Bone Marrow Transplantation*, 11:497-499, 1993
133. Winston DJ, **Chandrasekar PH**, Lazarus HM, Goodman JL, Silber JL, Horowitz H, Shadduck RK, Rosenfeld CS, Ho WG, Islan MZ, Buell DN. Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Placebo-Controlled, Double-Blind, Multicenter Trial. *Annals of Internal Medicine*, 118:495-503, 1993
134. Molinari JA, Cottone JA, **Chandrasekar PH**. Tuberculosis in the 1990's: Current Implications for Dentistry. *Compendium of Continuing Education for Dentistry*, XIV:276-294, 1993.
135. Touchette MA, **Chandrasekar PH**, Milad MA, Edwards DJ. Contrasting Effects of Fluconazole and Ketoconazole on Phenytoin and Testosterone Disposition in Man. *British Journal of Clinical Pharmacology*, 34:74-78, 1992
136. Knoll-Vlachos S, **Chandrasekar PH**. Adult Leukemia Due to Human Lymphotropic Virus Type-1 (HTLV-1): An Increasing Problem. *Primary Care & Cancer*, March 1992

Original Observations in Refereed Journals (continued)

137. Goodman JL, Winston DJ, Greenfield RA, **Chandrasekar PH**, Fox B, Kalzer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JL, Horowitz H, Lichtin A, Wolff SN, Mangan KF, Silver SM, Weisdorf D, Ho WG, Gilbert G, Buel D. Does Fluconazole Prevent Infections in Patients Undergoing Bone Marrow Transplants? Results of a Randomized Controlled Trial. *N Engl J Med*, 326:845-851, 1992
138. Walsh TJ, Hathorn JW, Sobel JD, Merz WG, Sanchez V, Maret SM, Buckley HR, Pfaller MA, Schaufele R, Sliva C, Navarro E, Leggiones J, **Chandrasekar PH**, Lee J, Pizzo PA. Detection of Circulating Candida Enolase by Immunoassay in Patients with Cancer and Invasive Candidiasis. *N Engl J Med*, 324:1026-1031, 1991
139. **Chandrasekar PH**, Sluchak JA: In Vitro Susceptibility of Cefoperazone Susceptible and Resistant Gram-Negative Rods to Cefoperazone Plus Sulbactam, Other, Aminoglycosides and Quinolones. *Infection*, 19:49-53, 1991
140. Ahmed AJ, Kruse JA, Haupt MT, **Chandrasekar PH**, Carlson RW: Hemodynamic Response to Gram-Positive Versus Gram-Negative Sepsis in Critically Ill Patients. *Crit Care Med*, 19:1520-1525, 1991
141. **Chandrasekar PH**, Cronin SM. Nephrotoxicity in Bone Marrow Transplant Recipients Receiving Aminoglycoside Plus cyclosporine or Aminoglycoside Alone. *Journal of Antimicrobial Chemotherapy*, 27:845-849, 1991
142. Poplin EA, Gordon CJ, Piskorowski TJ, **Chandrasekar PH**. Pneumocystis carinii Pneumonia in Non-AIDS Patients with Solid Tumors. *Cancer*, 68:193-4, 1991
143. **Chandrasekar PH**. Office Management of Apparently Health Persons with Human Immunodeficiency Virus Infection. *AIDS Med Report*, 3(10):115-122, 1990
144. Rybak MJ, Albrecht LM, Boike SC, **Chandrasekar PH**. Analysis of Vancomycin Nephrotoxicity. *J Antimicrobial Chemother* 25: 679-687, 1990.
145. Chandrasekar PH, Molinari JA, Kruse JA. Risk Factors for Human Immunodeficiencies Virus Infection Among Parenteral Drug Abuser in a Low Prevalence Area. *Southern Medical Journal*, 83:996-1001, 1990
146. Brown RB, Kruse JA, Counts GC, Russell JA, Christian NV, Sands ML, **Endotracheal Tobramycin Study Group**. Double-Blind Study of Endotracheal Tobramycin in the Treatment of Gram-Negative Bacterial Pneumonia. *Antimicrobial Agents Chemother*, 24:269-272, 1990

Original Observations in Refereed Journals (continued)

147. **Chandrasekar PH**, Rudnick CA. How to Treat HIV-Infected Patients with Cardiovascular Problems. *AIDS Medical Report*, 2(10):112-116, 1989
148. **Chandrasekar PH**, Sluchak JA. In-Vitro Susceptibility and emergence of Resistance of Gram-Positive Cocci to Paldimycin. *J Antimicrob Chemother*, 24:821-824, 1989
149. **Chandrasekar PH**, Sluchak JA. New Agents Against Methicillin and/or Gentamicin-Resistant and Susceptible Staphylococci. *Chemotherapy*, 35:333-337, 1989
150. **Chandrasekar PH**. Nail Discoloration & Human Immunodeficiency Virus (HIV) Infection (Brief Communication). *Am J Med*, 86:506-507, 1989
151. **Chandrasekar PH**, Levine DP, Price S, Rybak MJ. Comparative Efficacies of Imipenem-Cilastatin and Vancomycin in Experimental Aortic Valve Endocarditis Due to Methicillin Resistant Staphylococcus aureus. *J Antimicrob Chemother*, 21:461-469, 1988
152. LeFrock JL, Smith BR, **Chandrasekar PH**, Rolston KVI, Molavi A, Kannangara DW. Efficacy and Safety of Aztreonam in the Treatment of Serious Gram-Negative Infections. *Arch Intern Med*, 147:325-328, 1987
153. **Chandrasekar PH**, Crane LR, Bailey EJ. Comparison of the Activity of antibiotic combinations In-Vitro with Clinical Outcome and Resistance Emergence in Serious Infection of Pseudomonas aeruginosa in Non-Neutropenic Patients. *J Antimicrob Chemother*, 19:321-329, 1987
154. Hess JA, **Chandrasekar PH**, Mortiere M, Molinari JA. Comparative Efficacy of Ketoconazole and Mebendazole in Experimental Trichinosis. *Antimicrobial Agents and Chemotherapy*, 30:953-954, 1986
155. **Chandrasekar PH**, Narula A: Bone and Joint Infections in Intravenous Drug Abuser. *Rev Inf Dis*, 8:904-911, 1986
156. **Chandrasekar PH**, Kruse JA, Mathews MF: Nosocomial Infections Among Patients in Different Types of Intensive Care Units at a City Hospital. *Crit Care Med*, 14:508-510, 1986
157. Unowsky J, **Chandrasekar PH**, DeLorenzo W, Levine DP: The In-Vitro and In-Vivo Activity of Coumermycin and Other Antibacterial Agents Against Methicillin-Resistant Strains of Staphylococcus aureus. *Chemotherapy*, 32:499-505, 1986
158. Rolston KVI, **Chandrasekar PH**, LeFrock JL. Clinical Features and Antimicrobial Therapy of Infections Caused By Group G Streptococci. *Infection*, 12:203-206, 1985

Original Observations in Refereed Journals (continued)

159. **Chandrasekar PH**, Price S, Levine DP. In-Vitro Evaluation of HR 810, Teicoplanin and 4 Other antimicrobials Against enterococci. *J Antimicrob Chemother*, 16:179-182, 1985
160. **Chandrasekar PH**, Smith B, LeFrock JL, Carr B. Enterococcal Super Infection and Colonization with Aztreonam Therapy. *J Antimicrob Agents Chemother*, 26:280-282, 1984
161. LeFrock JL, Molavi A, Smith BR, Black P, Rosenberg M, Rolston KVI, Brodner R, **Chandrasekar PH**, Henao L, Kannangara DW. Effectiveness of Cefotaxime in Gram-Negative Meningitis. *Neurosurg*, 15:679-682, 1984
162. Rolston KVI, **Chandrasekar PH**, LeFrock JL. Antimicrobial Tolerance in Group C and Group G Streptococci. *J Antimicrob Chemother*, 13:389-392
163. LeFrock JL, McCloskey RV, Molavi A, Rosenberg M, Kannangara DW, Rolston KVI, **Chandrasekar PH**, Chokkavelu V. Cefmenoxime – Clinical, Bacteriologic, and Pharmacologic Studies. *Am J Med*, 77:72078, 1984
164. LeFrock JL, Molavi A, Smith BR, Kannangara DW, Rolston KVI, **Chandrasekar PH**, Rosenberg M. Comparison of Mezlocillin and Cefoxitin in us of Obstetrical and Gynecological Infections. *Infections in Surgery*, 3:507-512, 1984
165. Chokkavelu V, **Chandrasekar PH**, Rolston KVI, LeFrock JL, Schell RF. Activity of Eleven Antimicrobial Agents Against Methicillin, Methicillin and Rifampin Resistant Staphylococcus aureus. *Chemother*, 30:97-101, 1984
166. **Chandrasekar PH**, Rolston KVI, Chokkavelu V, LeFrock JL, Kannangara DW. Comparative Efficacy of Four Antibiotics in Anaerobic Pulmonary Infection. *Chemother*, 30:331-336, 1984
167. **Chandrasekar PH**, Schell RF, Rolston KVI, Francisco M. Comparative In-Vitro Activities of Cefsulodin, B-Lactams and Aminoglycosides Against Pseudomonas aeruginosa. *Chemother*, 30:165-169, 1984
168. **Chandrasekar PH**, Rolston KVI, Smith BR, LeFrock JL. Ceftriaxone Penetration Cerebrospinal Fluid Across Inflamed and Non-Inflamed Meninges. *J Antimicrob Chemother*, 14:427-430, 1984
169. Rolston KVI, **Chandrasekar PH**, LeFrock JL, Schell RF. Activity of Ceftazidime, Other B-Lactams and Aminoglycosides Against Pseudomonas aeruginosa. *Chemother*, 30:31-34, 1984
170. Rolston KVI, **Chandrasekar PH**, Smith BR, LeFrock JL. Cefmenoxime Penetration into Cerebrospinal Fluid Across Non-Inflamed Meninges. *J Antimicrob Chemother*, 12:519-521, 1983

Original Observations in Refereed Journals (continued)

171. LeFrock JL, Molavi A, Rolston KVI, Smith BR, Schell RF, **Chandrasekar PH**, Carr B. In-Vitro and In-Vivo Comparison of Mezlocillin and Cefoxitin. *J Antimicrob Chemother*, 11 (Suppl C), 1983
172. LeFrock JL, Molavi A, Lentnek A, Rolston KVI, **Chandrasekar PH**, Kannangara DW, Schell RF, Oaks SS, Carr BB. Comparative Study of Ceftizoxime and Cefamandole in the Treatment of bronchopulmonary Infections. *J Antimicrob Chemother*, 10(5):215-221, 1982

Multicenter Study Participant

1. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann, Walsh TJ **et al**. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. *N Engl J of Med*, 356:348-359, 2007
2. Lipsky BA, Itani K, Norden C, and the **Linezolid Diabetic Foot Infections Study Group**. Treating Foot Infections in diabetic Patients: A Randomized, Multicenter, Open-Label Trial of Linezolid versus Ampicillin-Sulbactam/Amoxicillin-Clavulanate. *Clin Infect Dis*, 38:17-24, 2004
3. Walsh TJ, Pappas P, Winston DJ, **et al**. Voriconazole compared with Liposomal Amphotericin B for empirical Antifungal Therapy in Patients with neutropenia and Persistent Fever. *New Engl J Med*, 346:225-234, 2002
4. Bone RC, Balk RA, Fein AM, Perl TM Wenzel RP, Reines HD, Quenzer RW, Iberty TJ, Macintyre N, Schien RMH, **The E5 Sepsis Study Group**. A Second Large controlled Clinical Study of E5, a Monoclonal Antibody to Endotoxin: Results of a Prospective, Multicenter, Randomized, Controlled Trial. *Critical Care medicine*, 23:994-1005, 1995
5. Greenman RL, Schein R, Martin MA, Wenzel RP, Macintyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell JA and the **XOMA Sepsis Study Group**. A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis. *J Am Med Association*, 266:1097-1102, 1991
6. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JR, Hyslop N, Jacobson JM, Hefner R, Dismukes WE, **The NIAID Mycoses Study Group and The AIDS Clinical Trials Group**. Comparison of Amphotericin B with Fluconazole in the Treatment of Acute AIDS-Associated Cryptococcal Meningitis. *N Engl J Med*, 326:83-89, 1992

Letters to the Editor

1. **Chandrasekar PH. Bad News to Worse News: 2015 Infectious Diseases (ID) Fellowship Match Results. Clin Infect Dis 2015. Jan 28. [Epub ahead of print] In press**
2. **Rupali P, Chandrasekar PH, Patel D. Voriconazole Toxicity Masquerading as Septic Shock. Leukemia and Lymphoma. 59:1593-8, 2014**
3. **Chandrasekar PH. Case 12 – 2013: A Woman with Pulmonary Infiltrates and Respiratory Failure. N Engl J Med 583-4, 2013**
4. **Chandrasekar PH, Revankar SG. Cryptococcosis in Febrile Renal Transplant Recipient. JAMA 310:7:748, 2013**
5. Alangaden G, **Chandrasekar PH.** Case 10-2010: A Woman with Weakness and a Mass in the Brain. N Engl J Med, 364:395-96, 2010
6. Ullmann AJ, **Chandrasekar PH,** Patino H. Posaconazole Prophylaxis in Hematologic Cancer. N Engl J Med, 356:2214-18, 2007
7. Vishnubhotla P, Ibrahim R, **Chandrasekar PH.** Fever and Eosinophilia Associated with Voriconazole Therapy. Annals of Pharmacotherapy, 38:900-901, 2004
8. Ibrahim R, Abella S, **Chandrasekar PH.** Tacrolimus-Clarithromycin Interaction in a Bone Marrow Transplant Patient. Annals of Pharmacotherapy, 36:1971-1972, 2002
9. **Chandrasekar PH.** Empiric antifungal Therapy for Persistent Fever in Neutropenic Patients. Clinical Infectious Diseases, 32:320-321, 2001
10. **Chandrasekar PH.** Use of Vancomycin in Central Venous Catheter-Related Infections. Bone Marrow Transplantation, 17:299, 1996
11. **Chandrasekar PH.** Quinolone Prophylaxis During Neutropenia. Ann Intern Med, 115:833, 1991
12. **Chandrasekar PH.** Low-Back Pain and Intravenous Drug Abuser. Arch Int Med, 150:1125-1128, 1990
13. **Chandrasekar PH,** Cushing R. Captopril and Glomerulitis. Ann Intern Med, 112:550, 1990
14. Harvey R, **Chandrasekar PH.** Chronic Meningitis Caused By Listeria in a HIV Infected Patient. Letter to the Editor. J Infect Dis, May, 1988
15. **Chandrasekar PH.** “Cure” of Chronic Cryptosporidiosis During Treatment with Azidothymidine (AZT) in a Patient with AIDS – Letter to the Editor. Am J Med, 83:187, 1987
16. **Chandrasekar PH.** Intravenous Immunoglobulin in Gram-Negative Bacteremia. Letter to the Editor. Ann Int Med, 113:877, 1990

17. **Chandrasekar PH**, Rybak MJ, Frankowski JJ. WBC Count and Vancomycin Letter to the Editor. *Am J Med*, 81:1114, 1986

#### Review Articles

1. **Buensalido JL, Chandrasekar PH.** Helicobacter pylori Infection Treatment. eMedicine from WebMD updated August 8, 2014. Available at <http://emedicine.medscape.com/article/2172395-overview>
2. **Krishnan Natesan S, Chandrasekar PH.** Chikungunya Virus. eMedicine from WebMD updated August 11, 2014. Available at <http://emedicine.medscape.com/article/2225687-overview>.
3. **Herchline TE, Swaminathan S, Chandrasekar PH.** Cellulitis. eMedicine from WebMD Updated April 1, 2014. Available at: <http://emedicine.medscape.com/article/214222-overview>
4. **Chandrasekar PH, Cavaliere R, Rust RS, Swaminathan S.** Haemophilus Meningitis. eMedicine from WebMD Updated December 13, 2013. Available at: <http://emedicine.medscape.com/article/1164916-overviewherchline>
5. **Herchline TE, Swaminathan S, Chandrasekar PH.** Cellulitis. eMedicine from WebMD Updated December 9, 2013. Available at: <http://emedicine.medscape.com/article/214222-overview>
6. **Clauss HE, Samuel R, Alangaden GJ, Chandrasekar PH, Truant AL, Jungkind D, Suh B.** Infections in Liver, Kidney, Pancrease, and Intestinal Transplant Recipients. *Clinical Microbiology Newsletter*, 35:7:53-59, 2013
7. **Chandrasekar PH, Polenakovic H, Polenakovic S.** Strongyloidiasis. eMedicine from WebMD. Updated March 8, 2013. Available at: <http://emedicine.medscape.com/article/229312-overview>
8. **Jacinto P, Chandrasekar PH.** Safety of Posaconazole. *Expert Opin Drug Saf*, 12:2:265-74, 2013
9. **Chandrasekar PH, Manavathu EK.** Caspofungin. *Drugs of Today*, 38(12):829-846, 2002
10. **Chandrasekar PH, Randich CA.** An Update on Antibiotics: Part II. *Hospital Physician*, 33(2):42-48, 1997
11. **Randich CA, Chandrasekar PH.** An Update on antibiotics: Part 1 *Hospital Physician*, 33(1):19-30, 1997
12. **Butler S, Molinari JA, Plezia RA, Chandrasekar PH, Venkat H.** Condyloma Acuminatum in the Oral Cavity: Four Case Reports and Review of Literature. *Rev Inf Dis* 10:344-350, 1988
13. **Komshian SV, Chandrasekar PH, Levine DP.** Adenovirus Pneumonia in Health Adults. *Heart & Lung*, 16:146-150, 1987



Review Articles (continued)

14. **Chandrasekar PH**, Arathoon E, Levine DP. Infections due to Achromobacter xylosoxidans. *Infections*, 14:279-282, 1986
15. **Chandrasekar PH**, Molinari JA. Endogenous Anaerobes in Orofacial Infections. *Infections in Surgery*, 5:217-282, 1986
16. **Chandrasekar PH**, LeFrock JL: Treatment of Anaerobic CNS Infections. *Indian J Pathol Microbiol*, 1985
17. **Chandrasekar PH**, Rolston KVI, Kannagara DW, LeFrock JL, Binnick SA. Hot Tub Associated Dermatitis Due to Pseudomonas aeruginosa: Case Reports and Review of the Literature. *Arch Dermatol*, 120:1337-1340, 1984
18. **Chandrasekar PH**, Pulimood BM. Miliary Tuberculosis. *Christian Medical College and Hospital Alumni Journal*, 1976

Books & Chapters

1. **Krishnan Natesan S, Chandrasekar PH. An Appraisal of the Current Guidelines for the Use of Antifungals in the Treatment of Invasive Fungal Infections due to Candida, Aspergillus, and Mucor. Fungal Infections in Asia The Eastern Frontier of Mycology, Editor Arunaloke Chakrabarti. Elsevier, pg 234-250, 2013**
2. **Chandrasekar PH**, Alangaden G. Managing Infections in Patients with Hematological Malignancies: Bacteria. *Contemporary Hematology*. Edited by Kleinberg M., Humana Press, Totowa, NJ, 2010
3. **Chandrasekar PH**, Manavathu EK. Antifungal Resistance – Aspergillus. *Antimicrobial Resistance*. Edited by Sobel J, Lerner SA, 2008
4. Alangaden GJ, **Chandrasekar PH**. *Cumitech – Infections in Renal/Pancreas/Intestinal Transplant Recipients*, 2007
5. **Chandrasekar P H** (Editor). Chapters on: Bone Infections – Author: Alangaden GJ, Joint Infections – Author Krishnan S. In a Page *Infectious Diseases*. Ed. McCue ID & Kahan S. Lippincott Williams & Wilkins, pp. 104-113, 2007
6. **Chandrasekar PH**. Fungi – Other Than Candida and Aspergillus: Management of Infections in Oncology Patients. Edited by Wingard JR, Bowden RA. Martin Dunitz (Taylor & Francis Group) London & New York. Pg 203-221, 2003
7. Kak V, **Chandrasekar PH**. Bone and Joint Infections in Intravenous Drug Abusers. *Infections in Injection Drug Users*. *Inf Dis Clin N America*, September 2002.

Books & Chapters (continued)

8. **Chandrasekar PH.** Chapter Herpes Infections. In Saunders Manual of Critical Care W.B. Saunders Co., Philadelphia, PA, pg 350, 2002
9. **Chandrasekar PH.** Chapter: Infections in Bone Marrow Transplant Patients (BMT). In Saunders Manual of Critical Care. W.B. Saunders Co., Philadelphia, PA, pg 365, 2002
10. Molinari JA, **Chandrasekar PH.** Chapter on Re-Emergence of Mycobacterium Tuberculosis Infection as a Major Occupational Risk for Health Professionals. In: Oral Manifestations of HIV Infection. John Greenspan and Deborah Greenspan (Editors), Quintessence Publishing Co., Chicago, Illinois, 1995
11. **Chandrasekar PH.** Chapter on infections in Non-Granulocytopenic Cancer Patients. In: The Principles and Practice of Medical Intensive Care. RW Carlson and MA Geheb (Editors) WB Saunders Co., Philadelphia PA, 1993
12. **Chandrasekar PH.** Chapter on Skeletal Infections in Intravenous Drug Abusers. In: Infections in Intravenous Drug Abusers. DP Levine and JD Sobel (Editors), Oxford University Press, New York, NY, pp 306-326, 1991
13. Molinari JA, **Chandrasekar P H.** Neisseria, Essential Dental Microbiology, Appleton-Century-Croft, New York, Willett and White Publications Ltd., 1990
14. Molinari JA, **Chandrasekar PH .** Mycobacteria, Essential Dental Microbiology, Appleton-Century-Croft, New York, Willett and White Publications Ltd., 1990

Editor

1. **Woods CJ, Levy CS.** Streptococcus Group B Infections. eMedicine from WebMD. Updated January 24, 2013. Available at: <http://emedicine.medscape.com/article/229091-overview>
2. **Greenfield RA.** Sporotrichosis. eMedicine from WebMD. Updated January 11, 2012. Available at: <http://emedicine.medscape.com/article/228723-overview>
3. **Huh S, Lee S.** Toxocariasis. eMedicine from WebMD. Updated April 18, 2012. Available at: <http://emedicine.medscape.com/article/229855-overview>
4. **Sinave CP, Ferguson TM.** Streptococcus Group D Infections. eMedicine from WebMD. Updated January 12, 2012. Available at: <http://emedicine.medscape.com/article/229209-overview>
5. **Greenfield RA.** Sporotrichosis. eMedicine from WebMD. Updated January 11, 2012. Available at: <http://emedicine.medscape.com/article/228723-overview>

Editor (continued)

6. **Smith DS. Trichinosis. eMedicine from WebMD. Updated November 28, 2012. Available at: <http://emedicine.medscape.com/article/230490-overview>**

Educational Material

1. **Chandrasekar PH.** What's At Risk: [www.infectiousdiseasesnetwork.com/fungalrisk](http://www.infectiousdiseasesnetwork.com/fungalrisk) , 2010
2. **Chandrasekar PH.** Invasive Fungal Infections in HSCT Recipients: Improving Outcomes Through Prevention and Treatment. Robert Michael Educational Institute LLC and Postgraduate Institute for Medicine. CE Activity, October 2009
3. **Chandrasekar PH, Drew RH.** Preventing & Managing IFIs in the 21<sup>st</sup> Century: Progress in Prevention of Invasive Fungal Infections and Promise of New Diagnostic Techniques. Center for Independent Healthcare Education and Vemco MedEd. CME/CE Newsletter, Issue 1, 2009
4. WSU CME. Ocular Infection in an Orthotopic Liver Transplant Recipient, 2007
5. Am Acad of CME. Handout: Serious Fungal Infections: New Strategies to Optimize Treatment Outcomes AACME, 2006
6. WSU CME. Zygomycosis in a Stem Cell Transplant Patient, 2006
7. WSU CME. Invasive Fungal Infection in a Patient with Chronic Lymphatic Leukemia, 2006
8. WSU CME. Invasive Fungal Infection in a Pediatric Patient with Leukemia, 2006
9. WSU CME. Invasive Fungal Infection in a Lung Transplant Recipient, 2006
10. Knowing Your Antifungal Agents: A Primer for Hematology/Oncology Clinicians. Medical College of Wisconsin. CME Program 2006
11. Managing Infections in Hematological Malignancies: Risk Adjusted Approaches. Rising Threat of MRSA in the Seriously Ill Patient. Academy for Health Care Education. CME CD-ROM, 2004 (Attached to Blood (Dec 2004) & Clin Inf Dis. (Dec 2004)
12. Exploring a Paradigm for the Prevention and Treatment of Aspergillosis Monograph. CME: Maryland State Medical Society, 2004
13. A Primer on Aspergillus – CD – ROM. Wayne State University CME Program.
14. Audiotape on "Tuberculosis" for the Academy of General Dentistry, 1994
15. Brochure – Autologous Bone Marrow Transplantation (BMT) and HSV-1 Reactivation – A Case Study, published September 1993, Burroughs Wellcome Co.

Educational Material (continued)

16. Brochure – Ostogenic Sarcoma and Adolescent Varicella – A Case Study, published September 1993, Burroughs Wellcome Co.
17. Scientific Exhibit – Reduction of Candidal Colonization with Fluconazole In neutropenic Cancer Patients. American Society for Hospital Pharmacists, Annual Meeting, Washington, DC, June 1992
18. Scientific Exhibit – Comparative In-Vitro Activity Cefoperazone/Sulbactam, Betalactams, Aminoglycosides & Quinolone Against Susceptible and Resistant Gram-negative Rods. 89<sup>th</sup> Annual meeting of the American society for Microbiology, New Orleans, Louisiana, May, 1989
19. A Guidebook on antibiotics, Division of Infectious Diseases, Published by Department of Internal Medicine. Wayne State University, 1987 – updated 1989
20. Audiotape on “The HIV Positive Patient” for Academy of General Dentistry, 1988
21. Photograph of Hot Tub Dermatitis. In: Microbiology, Fifth Edition, Editors Wistreich GA and Lechtman MD. Macmillan Publishing Corp., New York 1988

Case Reports

1. **Iyer SP, Movva K, Wiebel M, Chandrasekar PH, Alangaden GJ, Carron M, Tranchida P , Revankar SG. Cryptococcal meningitis presenting as sinusitis in a renal transplant recipient. *Transpl Infect Dis* 15:E187-E190, 2013**
2. **Alhousseini M, Chandrasekar PH. Catheter-related Bloodstream Infection Due to Mycobacterium Neoaurum in a Patient with Acute Leukemia. *Leuk Lymphoma* 2014 12:151-4, e-pub 2013 ahead of print [dio: 10.13109/10428194.2013.858153](https://doi.org/10.13109/10428194.2013.858153)**
3. **Chordia P, Chandrasekar PH. Status Epilepticus due to Severe HHV-6 Encephalitis in an Allogeneic Stem Cell Transplant Recipient. *Mediterr J Hematol Infect Dis*, 2014, 6(1): e2014008**
4. **Slomka JM, Laker S, Chandrasekar PH, Paull DE. Failure to Obtain Microbiologic Culture and its Consequence in a Mesh-Related Infection. *Accepted, BMJ Case Reports* 2013 published on *line*.[dio: 10.1136/bcr-2013-009123](https://doi.org/10.1136/bcr-2013-009123)**
5. **Suramaethakul N, Chandrasekar PH. Bandlike Erythema Over the Abdominal Wall. *Infectious Diseases Clinical Practice* 21:41-42, 2013**
6. Salimnia H, Alangaden GJ, Bharadwaj R, Painter TM, **Chandrasekar PH**, Fairfax MR. Weissella confusa: An Unexpected Cause of Vancomycin-Resistant Gram-positive Bacteremia in Immunocompromised Hosts. *Transplant Infectious Diseases*, 13 (3):294-8, 2011, E-pub Dec 13, 2010

Case Reports (continued)

7. Chopra T, Taormina M, **Chandrasekar PH**. Genital Ulcers Progress to Fatal Sepsis During Treatment with All-Trans Retinoic Acid (ATRA) for Acute Promyelocytic Leukemia. *Infect Dis in clinical Practice*, 19:170-71, 2010
8. Patel D, Fairfax M, **Chandrasekar PH**, Salimnia H, Lephart PR. *Listeria grayi*: Vancomycin-Resistant, Gram-Positive Rod Causing Bacteremia in a Stem Cell Transplant Recipient. *Transpl Infect Dis*, 12:6:526-8, 2010
9. Chopra T, **Chandrasekar PH**. Salmon Colored Rash in a Young Woman. *Infect Dis Clin Pract*, 18:193-194, 2010
10. Chopra T, **Chandrasekar PH**. Images in Infectious Disease: Pseudomonas Dacryocystitis in a Woman with Ovarian Cancer. *Infect in Med*, 26:127, 2009
11. Narreddy S, **Chandrasekar PH**. False-positive Aspergillus Galactomannan (GM) Assay in Histoplasmosis. *J Infect*, 56:80-1, 2008
12. Cronin SM, Abidi MH, Shearer CJ, **Chandrasekar PH**, Ibrahim RB. Rhodococcus Equi Lung Infection in an Allogeneic Hematopoietic Stem Cell Transplant Recipient. *Transpl Infect Dis*, 10:48-51, 2008
13. Buhari M A, Varon N, **Chandrasekar PH**. CNS Blastomycosis Presenting as Cerebral lesions in an HIV-Seronegative Homeless Patient. *Infect Med*, 24:8(S)12-14, 2007
14. Atallah E, Choi M, Akins B, **Chandrasekar PH**. Mycosis from Marijuana Diagnosed by PCR. [www.frontlinefungus.org](http://www.frontlinefungus.org) 2006
15. Krishnan S, Barger G, **Chandrasekar PH**. Recurrent Strongyloidiasis Stercoralis Hyperinfection Syndrome: Case Report and Brief Review. *Inf Dis Clin Pract*, 14(4):240-243, 2006
16. Mahesh S, Madan S. **Chandrasekar PH**. Zygomycosis Following Nasogastric Tube Placement in a Cancer Patient. *Infect. Med*, 22:40-42a, 2005
17. Villanueva A, **Chandrasekar PH**. Parvovirus B19 Infection Presenting as Aplasia and Pain Crisis in a Patient with Sickle Cell Disease. *Hospital Physician*, June 1999 pp. 64-71
18. **Chandrasekar PH**, Alangaden G, An T. Herpes-Associated Erythema Multiforme. *Infectious Diseases in Clinical Practice*, 7:295-297, 1998
19. Ramnath N, Momin F, Karanes C, Lundstrom T, **Chandrasekar PH**. Fatal Mucormycosis (Zygomycosis) after Intravascular Catheterization in a Transplant Recipient. *Infections in Medicine*, 15:252-255, 1998

Case Reports (continued)

20. Lundstrom TS, Fairfax MR, Dugan MC, Vazquez JA, **Chandrasekar PH**, Abella E, Kasten-Sportes C. *Phialophora verrucosa* Infection in a BMT Patient. Bone Marrow Transplantation, 20:789-791, 1997
21. Naik H, **Chandrasekar PH**. Herpes Simplex Virus (HSV) Colitis in a BMT Recipient. Bone Marrow Transplantation, 17:285-286, 1996
22. **Chandrasekar PH**. Lower Extremity Rash in a Health Woman. Infectious Diseases in Clinical Practice, 3:43, 1994
23. **Chandrasekar PH**. Sore Throat and Hoarseness in a Patient Undergoing Bone Marrow Transplantation. Primary Care and Cancer, 14:54-56, 1994
24. **Chandrasekar PH**. Extrapulmonary Pneumocystosis. AIDS Reader, 2(3):94-98, 1992
25. Bazzi MN, **Chandrasekar PH**. Fever and Supraclavicular Mass in a Young Man. An Infrequently Identified Etiology. Hosp Practice, March 15, pp94-102, 1991
26. **Chandrasekar PH**, Molinari JA, Jelinek MT. Polymicrobial Anaerobic Bacteremia Following Urethral Instrumentation. Infections in Urology, March/April 4753, 1990
27. Pilla A, Rybak MJ, **Chandrasekar PH**. Spiramycin in the Treatment of Cryptosporidiosis. Pharmacotherapy, 7:188-190, 1987
28. Rybak MJ, Bowles SK, **Chandrasekar P H**, Edwards DJ. Increased Theophylline Concentrations Secondary to Ciprofloxacin. Drug Intelligence and Clinical Pharmacy, 21:879-881, 1987
29. **Chandrasekar PH**, Molinari JA. Corynebacterium Hemolyticum Bacteremia with Fatal Neurologic Complications in an Intravenous Drug Addict. Am J Med 82:638-640, 1987
30. **Chandrasekar PH**, Kannagara DW, LeFrock JL, Rolston KVI. Medical Treatment of Brain Abscess with Metronidazole. Infections in Surgery, 927-930, December 1983
31. Kiel RJ, **Chandrasekar PH**, Levine DP. Unusual Complications of Hickman Catheter Use. Infections in Surg 5:465-466, 1986
32. **Chandrasekar PH**, Molinari JA. Oral Candidiasis – Fore Runner of AIDS? Oral Surg Oral Pathol, 60:532-534, 1985
33. Gutschi LM, **Chandrasekar PH**. Sciatic Nerve Damage with Pentamidine Administration – Letter to the Editor. Drug Intelligence and Clin Pharmacy, 19:762, 1985

Editorial

1. **Buensalido J, Chandrasekar PH. Prophylaxis Against Hepatitis B Reactivation Among Patients with Lymphoma and Receiving Rituximab. Expert Rev Anti Infect Ther, 12:151-4, 2014,**
2. Ramesh M, **Chandrasekar PH.** Effective Alternates to Trimethoprim-Sulfamethoxazole as Antimicrobial Prophylaxis in Stem Cell Recipients.: Are There Any? *Pediatr Transplant*, 12:823-826, 2008
3. **Chandrasekar PH,** Pulimood BM. Gas Cysts of the Intestine. *J Assoc Physicians of India*, November, 1976
4. **Chandrasekar PH,** Pulimood BM. Tuberculosis of Colon—Common or Uncommon? *J Assoc Physicians of India*, September, 1976

Book Review

1. The Year in Infection, Volume 2. 2005 Clinical Publishing, Oxford, UK. *Clin Infect Dis*, 41:1369, 2005
2. Physician's 1992 Drug Handbook. Springhouse Corporation, Springhouse, Pennsylvania. In *The Journal of Pharmacy Technology*, 8:149-150, 1992

**PUBLISHED ABSTRACTS**

Abstract List Discontinued After 2001

1. Winston DJ, Maziarz R, **Chandrasekar PH,** Bhimer J, et al. Long-Term Antifungal Prophylaxis in Allogeneic Bone Marrow Transplant Patients. A Multicenter, Randomized Trial Of Intravenous/Oral Itraconazole vs. Intravenous/Oral Fluconazole. *American Society Hematology*, December 2001
2. Manavathu EK, Ganesan LT, Cutright JL, **Chandrasekar PH.** In Vitro Antifungal Activity of Voriconazole in Two-Drug Combination with Micafungin, Caspofungin and Amphotericin B. IN: *Programs and Abstracts of the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy*, December 16-19, 2001, Illinois. Abstract J-125
3. Cutright JL, Manavathu EK, **Chandrasekar PH.** In Vivo Virulence of Laboratory-Selected Azole-Resistant *Aspergillus fumigatus* In a Murine Pulmonary Aspergillosis Model. IN: *Programs and Abstracts of the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy*, December 16-19, 2001, Chicago, Illinois. Abstract J-1613

Published Abstracts (continued)

4. Varanasi NL, Baskaran I, Alangaden GJ, Thomas PA, **Chandrasekar PH**, Manavathu EK. In Vitro Susceptibility and Azole Resistance Among Clinical And Laboratory-Selected Isolates of *Aspergillus flavus* Obtained From Three Continents. IN: Programs and Abstracts of the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, Illinois. Abstract J-217
5. Ramesh MS, Baskaran I, Ganesan LT, Manavathu EK, **Chandrasekar PH**. Post Antifungal Effect of Older and New Antifungal Agents On *Aspergillus Fumigatus* and *Candida albicans*. IN: Programs and Abstracts of the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, Illinois. Abstract J-105
6. Manavathu EK, Baskaran I, Alangaden GJ, **Chandrasekar PH**. Molecular Characterization of Laboratory Isolates of *Aspergillus fumigatus* Showing Reduced Susceptibility to Voriconazole. IN: Programs and Abstracts of 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and chemotherapy, December 16-19, 2001, Chicago, Illinois. Abstract J-817
7. Varanasi NL, Baskaran I, Alangaden GJ, **Chandrasekar PH**, Manavathu EK. Novel Effect of Voriconazole on Conidiation and Pigmentation of *Aspergillus* Species. IN: Programs and Abstracts of the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, Illinois. Abstract J-816
8. Manavathu EK, Baskaran I, Alangaden GJ and **Chandrasekar PH**. Differential Susceptibility of Itraconazole Resistant *Aspergillus fumigatus* Isolates to Triazoles. IN: Programs and Abstracts of the 101<sup>st</sup> General Meeting of the American Society for Microbiology, May 20-24, 2001, Orlando, Florida, Abstract A-18
9. Manavathu EK, Baskaran I, Alangaden GJ, **Chandrasekar PH**. Molecular Characterization of the P450-Dependent Lanosterol Demethylase Gene From Clinical Isolates of *Aspergillus fumigatus*. IN: Programs and Abstracts of the 101<sup>st</sup> General Meeting of the American Society for Microbiology, May 20-24, 2001, Orlando, Florida. Abstract F-20
10. Alangaden GJ, Jamma K, **Chandrasekar PH**, Karanes C, Klein J, Cassells L, Dansey R, Abella S, Peters W, Baynes R. *Clostridium difficile* Associated Diarrhea During Hematopoietic Stem Cell Transplantation. IN: Programs and Abstracts of the 38<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, September 7-10, 2000, New Orleans, Louisiana. Abstract #395
11. Alangaden GJ, Thompson E, Yoon S, Akins R, **Chandrasekar PH**, Vazquez J. Diagnosis of Invasive Fungal Infections by Detection of Fungal DNA in Clinical Specimens Using A Species-Specific PCR. IN: Programs and Abstracts of the 38<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, September 7-10, 2000, New Orleans Louisiana. Abstract #273



Published Abstracts (continued)

12. **Chandrasekar PH**, Cutright JL, Manavathu EK. Antifungal Susceptibility, Frequency of Isolation and Species Diversity of Clinical Isolates of *Aspergillus* at The Detroit Medical Center Over A 6-Year Period (1994-1999). IN: Programs and Abstracts of the 11<sup>th</sup> International Symposium on Infections in the Immunocompromised Host. Halifax, Nova Scotia, Canada. June 19-21, 2000
13. Manavathu EK, Krishnan S, Cutright JL, **Chandrasekar PH**. A Comparative Study of the In Vitro Susceptibility of *Aspergillus fumigatus* to Antifungal Agents Individually and in Combinations by the Fractional Inhibitory Concentration Index, Tetrazolium Reduction and Radiometric Assays. IN: Programs and Abstracts of the 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000. Abstract No. 931
14. Manavathu EK, Dimmock JR, Cutright JL, **Chandrasekar PH**. Proton-Translocating-ATPase-Targeted Antifungal Activity of a Novel Conjugated Styryl ketone: Kinetics of Inhibition of *Candida albicans* H<sup>+</sup>-ATPase. IN: Programs and Abstracts of the 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000. Abstract No. 1095
15. Moosa MYS, Alangaden GJ, Manavathu EK, Cutright JL, **Chandrasekar PH**. Does Emergence of Resistance to Amphotericin B During Treatment For Invasive Aspergillosis Contribute to a Poor Outcome? IN: Programs and Abstracts of the 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000
16. Chilukuri S, Alangaden GJ, Karanes C, Klein J, Cassells L, Dansey R, Abella S, Peters W, Baynes R, **Chandrasekar PH**. Antifungal Chemoprophylaxis in Bone Marrow/Stem Cell Transplantation: An International Survey. IN: Programs and Abstracts of the 11<sup>th</sup> International Symposium of Infectious in the Immunocompromised Host. Halifax, Nova Scotia, June 18-21, 2000
17. Manavathu EK, Krishnan S, Cutright JL, **Chandrasekar PH**. A Comparative Study of the In Vitro Susceptibility of *Aspergillus fumigatus* to Antifungal Agents Individually and in Combinations. IN: Programs and Abstracts of the 11<sup>th</sup> International Symposium on Infections in the Immunocompromised Host, Halifax, Nova Scotia, Canada, June 18-21, 2000
18. **Chandrasekar PH**, Cutright JL, Manavathu EK. Antifungal Susceptibility, Frequency of Isolation and Species Diversity of Clinical Isolates at Detroit Medical Center over a 6-Year Period. IN: Programs and Abstracts of the 11<sup>th</sup> International Symposium on Infections in the Immunocompromised Host. Halifax Nova Scotia, Canada, June 18-21, 2000
19. Jamma K, **Chandrasekar PH**, Karanes C, Klein J, Cassells L, Dansey R, Abella S, Peters W, Baynes R, Alangaden GJ. Spectrum of *Clostridium difficile* Diarrhea During Stem Cell Transplants (SCT). IN: Programs and Abstracts of the 11<sup>th</sup> International Symposium on Infections in the Immunocompromised Host. Halifax, Nova Scotia, Canada, June 18-21, 2000

Published Abstracts (continued)

20. Winston DJ, Yeager AM, **Chandrasekar PH**, Snyderman D, Peterson FB, and the Valaciclovir Study Group. Randomized Comparison for Prophylaxis of CMV Disease and Other Complications after Allogeneic Bone Marrow Transplantation. 2<sup>nd</sup> International Conference on Transplant Infectious Diseases, Stockholm Sweden, May 2000
21. Hidalgo JA, Alangaden GJ, Akins RA, Abrams GW, Elliott D, Puklin J, **Chandrasekar PH**, Vazquez JA. Diagnosis of Fungal Endophthalmitis by Detection of *Candida albicans* DNA in Vitreous Specimens Using a Species-Specific PCR. IN: Programs and Abstracts of 37<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, November 1999
22. Abraham OC, Klein J, Chalasani G, Cassells L, Dansey R, Abella S, Karanes C, Peters W, Baynes R, **Chandrasekar PH**. Infectious Complications in Women Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation (PBPCT) for Breast Cancer. IN: Programs and Abstracts of 37<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, November 1999
23. Wahiduzzaman M, **Chandrasekar PH**, Alangaden GJ. High Frequency of Gram-negative Bacterial Pneumonia in Bone Marrow/Stem Cell Transplant (BMT) Recipients with Graft-vs.-Host Disease (GVHD) and Pulmonary Aspergillosis. IN: Programs and Abstracts of 37<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, November 1999
24. Manavathu EK, Cutright JL, **Chandrasekar PH**. Species Diversity and In-Vitro Antifungal Susceptibility of Clinical Isolates of *Aspergillus* Obtained in a Medical Center from January 1994 to December 1998. IN: Programs and Abstracts of the 37<sup>th</sup> Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, September 26-29, 1999
25. Manavathu EK, Dimmock JR, **Chandrasekar PH**. H<sup>+</sup>-ATPase Dependent Activity of a Novel Conjugated Styryl Ketone Against *Cryptococcus neoformans*. IN: Programs and Abstracts of the 37<sup>th</sup> Annual Meeting of the Interscience Conference on antimicrobial Agents and Chemotherapy, San Francisco, California, September 26-29, 1999
26. Manavathu EK, Cutright JL, **Chandrasekar PH**. A Comparative Study of the In-Vitro Susceptibility of *Aspergillus* Species to SCH56592 (SCH), Amphotericin B (AMB), Itraconazole (ITZ) and Voriconazole (VCZ). 99<sup>th</sup> General Meeting of the American Society of Microbiology, Chicago, Illinois, May 30-June 3, 1999
27. Manavathu EK, Abraham OC, Cutright JL, **Chandrasekar PH**. Isolation and In-Vitro Susceptibility to Amphotericin B (AMB), Itraconazole (ITZ) and SCH56592 (SCH) of Voriconazole (VCZ)-resistant Laboratory Isolates of *Aspergillus fumigatus* 99<sup>th</sup> General Meeting of the American Society of Microbiology, Chicago, Illinois, May 30 – June 3, 1999

Published Abstracts (continued)

28. Kanno M, **Chandrasekar PH**, Alangaden GJ. Cytomegalovirus (CMV) Disease in Non-Transplant Recipients and non-HIV Patients. IN: Programs and Abstracts of the 36<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Denver, Colorado, November 1998
29. Manavathu EK, Dimmock JR, Vashishtha SC, Cutright JL, **Chandrasekar PH**. Proton Pumping ATPase Directed Fungicidal Activity of a Novel Conjugated Styryl Ketone. IN: Programs and Abstracts of the 38<sup>th</sup> Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 23-27, 1998
30. Bowden R, **Chandrasekar PH**, White M, J-A van Burik J, Wingard J, and the Multicenter Aspergillus Study Group. A Double-Blind, Randomized, Controlled Trial of Amphocil (ABCD) vs. Amphotericin B (AmB) for Treatment of Invasive Aspergillosis in Immunocompromised Patients. IN: Programs and Abstracts of the 10<sup>th</sup> International Symposium on Infections in the Immunocompromised Host Society, Davos, Switzerland, June 21-24, 1998.
31. Kumar A, Alangaden GJ, Akhtar A, Karanes C, Abella S, Dansey R, Klein J, Baynes R, **Chandrasekar PH**. Significance of Aspergillus in Clinical Specimens from Cancer Patients at a Tertiary Care Center. IN: Programs and Abstracts of the 10<sup>th</sup> International Symposium on Infections in the Immunocompromised Host Society, Davos, Switzerland, June 21-24, 1998
32. Manavathu EK, Cutright JL, **Chandrasekar PH**. In Vitro and In Vivo Resistance to Amphotericin B of a Mutant Isolate of *Aspergillus fumigatus*. In: Programs and Abstracts of the 10<sup>th</sup> International Symposium on Infections in the Immunocompromised Host Society, Davos, Switzerland, June 21-24, 1998
33. Ucar E, Karanes C, Abella S, **Chandrasekar PH**. Trends in Bacteremia Among Cancer/Marrow Transplant Patients During 1991 – 1995. IN: Programs and Abstracts of the 10<sup>th</sup> International Symposium on Infections in the Immunocompromised Host Society, Davos, Switzerland, June 21-24, 1998
34. Pulimood S, Alangaden G, **Chandrasekar PH**. Candidemia Due to Multiple Candidal species at a Tertiary Care Institution. IN: Programs and Abstracts of the 10<sup>th</sup> International Symposium on Infections in the Immunocompromised Host Society, Davos Switzerland, June 21-24, 1998
35. Pulimood S, Alangaden GJ, **Chandrasekar PH**. Changing Epidemiology of Candidemia at a Tertiary Care Institution. IN: Programs and Abstracts of the 10<sup>th</sup> International Symposium of Infections in the Immunocompromised Host Society, Davos, Switzerland, June 21-24, 1998
36. Manavathu EK, Vazquez JA, **Chandrasekar PH**. Reduced Susceptibility of *Aspergillus fumigatus* to Itraconazole Due to Decreased Intracellular Accumulation of the Antifungal Agent. IN: Programs and Abstracts for the 98<sup>th</sup> General Meeting of the American Society for Microbiology, Atlanta, Georgia, May 1998

Published Abstracts (continued)

37. Gnann J, Tyring S, Burdge D, **Chandrasekar PH**, Wallace M, Beutner K, Weiss H Soong S, Sherrill L, Laughlin C, Whitley R, and the CASG Herpes Zoster Study Group. Oral Antiviral Therapy for Herpes Zoster in Immunocompromised Patients: Sorivudine vs. Acyclovir. IN: Programs and Abstracts of the 35<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 1997
38. Manavathu EK, Cutright JL, Dimmock JR, **Chandrasekar PH**. In Vitro and In Vivo Susceptibility of *Aspergillus fumigatus* to a New Conjugated Styryl Ketone. IN: Programs and Abstracts of the 37<sup>th</sup> Annual Meeting of the Interscience Conference on antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28 – October 1, 1997
39. Manavathu EK, Cutright JL, **Chandrasekar PH**. A Comparative Study of the In-Vitro Susceptibility of Amphotericin B-Resistant Isolates of *Aspergillus fumigatus* to Voriconazole and Itraconazole. 37<sup>th</sup> Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28 – October 1, 1997
40. Abraham OC, Manavathu EK, **Chandrasekar PH**. In-Vitro Activities of Voriconazole, Itraconazole and Amphotericin B against *Aspergillus* Species. 35<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 1997
41. Manavathu EK, Cutright JL, **Chandrasekar PH**. Organism-Dependent Fungicidal Activity of Azoles. 35<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 1997
42. Diwakaran H, Saravanan SM, **Chandrasekar, PH**. Angioimmunoblastic Lymphadenopathy with Dysproteinemia in a Patient with AIDS: A Case Report. American College of Physicians Annual Meeting, Traverse City, Michigan, September 1997
43. Manavathu EK, Cutright JL, **Chandrasekar PH**. In-Vitro Susceptibility of Itraconazole-resistant Isolates of *Aspergillus fumigatus* to Voriconazole. 8<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland, May 25-28, 1997
44. Saker S, Puklin JE, **Chandrasekar PH**. Fatal Aspergillosis with Endophthalmitis in an Allogeneic Marrow Recipient. American College of Physicians Annual Meeting, Grand Rapids, Michigan, May 1997.
45. Villanueva A, Khierbek S, **Chandrasekar PH**. Parvovirus B-19 Infection in a Patient with Sickle Cell Diseases Presenting as Pain and Aplastic Crises: A Case Report. American College of Physicians Annual Meeting, Traverse City, Michigan, September 1996
46. Hathorn J, **Chandrasekar PH**, Baird I, Arnow P, Waskin H, and the Cefepime FN Study Group. Double-Blind Comparison of Cefepime vs. Ceftazidime to Treat Febrile Neutropenia. 26 Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 1996

Published Abstracts (continued)

47. Brohi S, **Chandrasekar PH**, BMT Team. Twice Weekly Ganciclovir Prophylaxis against Cytomegalovirus (CMV) Diseases in Allogeneic Bone Marrow Transplantation (BMT) Recipients. 9<sup>th</sup> International Symposium on Infections in the Immunocompromised Host. Assisi, Italy, June 1996
48. Brohi S, **Chandrasekar PH**, BMT Team. Infectious Complications in Recipients of Bone Marrow from Unrelated Donors. 9<sup>th</sup> International Symposium on Infections in the Immunocompromised Host. Assisi, Italy, June 1996
49. **Chandrasekar PH**, Prior L, Kraut M. Prospective Evaluation of Skin Test for Tuberculosis (PPD) in Patient with Head/Neck or Lung Malignancy. 9<sup>th</sup> International Symposium of Infections in the Immunocompromised Host. Assisi, Italy, June 1996
50. Ludstrom TS, Fairfax M, Vazquez JA, **Chandrasekar PH**, Abella S, Kasten-Sportes C. *Phialophora verrucosa* (PV) Causing Fatal Pulmonary Hemorrhage in a Bone Marrow Transplant (BMT) Patient. 33<sup>rd</sup> Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 1995
51. Abbas M, **Chandrasekar P H**, BMT Team. Respiratory Syncytial Virus (RSV) in a Bone Marrow Transplant (BMT) Unit, Winter, '94'95'. 33<sup>rd</sup> Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 1995.
52. Momin F, Khouhani M, Cherednikova L, **Chandrasekar PH**, and BMT Team. Toxoplasmosis in Bone Marrow Transplantation (BMT). 33<sup>rd</sup> Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 1995
53. **Chandrasekar PH**, Thompson E, Sivan C, Kraut M. Prospective Evaluation of Skin Test for Tuberculosis (PPD) in Patients with Head/Neck or Lung Malignancy. 33<sup>rd</sup> Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 1995
54. Brooks JV, **Chandrasekar PH**, Crane LR. Primary Central Nervous System (CNS) Lymphoma in AIDS. American Federation for Clinical Research, San Diego, California, May 1995
55. Momin F, Khouhani M, Cherednikova L, **Chandrasekar PH**, and BMT Team. Toxoplasmosis in Bone Marrow Transplantation (BMT). 33<sup>rd</sup> Annual Meeting of the 100
56. **Chandrasekar PH**, Thompson E, Sivan C, Kraut M. Prospective evaluation of Skin Test for Tuberculosis (PPD) in Patients with Head/Neck or Lung Malignancy. 33<sup>rd</sup> Annual Meeting of the Infectious Diseases Society of America, San Francisco, California, September 1995
57. Brooks JV, **Chandrasekar PH**, Crane LR. Primary Central Nervous System (CNS) Lymphoma in AIDS. American Federation for Clinical Research, San Diego, California, May 1995.

Published Abstracts (continued)

58. Kaptur C, Flanagan E, Bartley J, Lesperance M, **Chandrasekar PH**, Lundstrom T. Fungemias in Bone Marrow Transplant Patients in the Fluconazole Prophylaxis Era. 32<sup>nd</sup> Annual Meeting of the Infectious Diseases Society of America, Orlando, Florida, October 1994
59. **Chandrasekar P H**. Tuberculosis in Cancer/Transplant Patients. Tuberculosis Workshop. Satellite Symposium. 8<sup>th</sup> International Symposium on Infections in Immunocompromised Host, Davos, Switzerland, June 1994
60. Frey MJ, **Chandrasekar PH**, Bone Marrow Transplant Team. International Survey on Routine Screening Tests for Detection of Infection Prior to Bone Marrow Transplantation (BMT). 8<sup>th</sup> International Symposium on Infections in the Immunocompromised Host. Davos, Switzerland, June 1994
61. **Chandrasekar PH**, Sweet A, Bone Marrow Transplant Team. Prospective, Randomized Double-Blinded Study of Efficacy of Cefoperazone Plus Sulbactam vs. Ceftazidime in the Empiric Treatment of Febrile Neutropenic Patients. 8<sup>th</sup> International Symposium on Infections in the Immunocompromised Host. Davos, Switzerland, June 1994
62. Thompson E, Akhtar A, **Chandrasekar PH**, Bone Marrow Transplantation Team. Reduced Frequency of Administration of Ganciclovir for the Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplantation (BMT). 8<sup>th</sup> International Symposium on Infections in the Immunocompromised Host. Davos, Switzerland, June 1994
63. **Chandrasekar PH**, Weinmann AJ, Shearer CJ. Autopsy-Identified Infections in bone Marrow Transplant (BMT) Recipients. Annual Meeting of the Infectious Diseases Society of America. New Orleans, LA, October 1993
64. Weinmann AJ, **Chandrasekar PH**, BMT Team. Mycobacteria in Bone Marrow Transplantation (BMT). Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA October 1993
65. Sluchak JA, **Chandrasekar PH**. Comparative Activities of Sulbactam, Clavulanic Acid or Tazobactam plus Cefoperazone against Multi-Resistant, Aerobic Gram-Negative Bacilli. 93<sup>rd</sup> Annual Meeting of the American Society for Microbiology, Atlanta, GA May 1993
66. Sluchak JA, **Chandrasekar PH**. Bacterial Inoculum Size and Natural Course of Infection with E. coli and with Pseudomonas aeruginosa in a Neutropenic Mouse Model. 93<sup>rd</sup> Annual Meeting of the American Society for Microbiology, Atlanta, GA May 1993
67. Molinari JA, **Chandrasekar PH**. Re-emergence of Mycobacterium Tuberculosis Infection as Major Occupational Risk for Health Professionals. Second International Workshop on Oral Manifestations of HIV Infection, San Francisco, January 31 – February 3, 1993

Published Abstracts (continued)

68. Khaliq Y, Bailey EM, Alangaden GJ, **Chandrasekar PH**. Effect of Three Dosage Levels of Fluconazole on Fungal colonization in Bone Marrow Transplant Patients. American College of Clinical Pharmacy, 1993 Winter Practice and Research Forum, Ft. Lauderdale, Florida, February 1993
69. Gajewski LK, Bailey EM, Brown P, **Chandrasekar PH**. Determination of the Need for a Prospective DUE of Intravenous Immune Globulin at the Detroit Medical Center. 27<sup>th</sup> Annual American Society for Hospital Pharmacists, Orlando, Florida, December 1992
70. Naik H, **Chandrasekar PH**, BMT Team, Detroit Medical Center, Wayne State University School of Medicine, Detroit MI. successful Treatment with Foscarnet Against Acyclovir-Resistant Herpes Simplex Virus-I (HSV-1) Infection During Allogeneic Bone Marrow Transplantation (BMT). American College of Physicians, 38<sup>th</sup> Annual Michigan Scientific Meeting, Grand Traverse Village, Michigan, October 1992
71. Naik H, **Chandrasekar PH**, BMT Team, Detroit Medical Center, Wayne State University School of Medicine, Detroit, MI. Multiple Causes of Diarrhea During Allogeneic Bone Marrow Transplantation (BMT). American College of Physicians, 38<sup>th</sup> Annual Michigan Scientific Meeting, Grand Traverse Village, Michigan, October 1992
72. Shearer C, **Chandrasekar PH**, and BMT Team, Detroit Medical Center, Wayne State University School of Medicine, Detroit, MI. Cutaneous Alternariosis During Allogeneic Bone Marrow Transplantation (BMT). American College of Physicians, 38<sup>th</sup> Annual Michigan Scientific Meeting, Grand Traverse Village, Michigan, October 1992
73. Alangaden GJ, Shearer C, **Chandrasekar PH**, BMT Team, Detroit Medical Center, Wayne State University School of Medicine, Detroit, MI. Fungemia Among Bone Marrow Transplant (BMT) Recipients, 1989-1991. Effect of Low-Dose Fluconazole Prophylaxis. Interscience Conference on antimicrobial Agents and Chemotherapy, Anaheim, California, October 1992
74. Lerner SA, Levine DP, McNeil P, Rybak MJ, **Chandrasekar PH**, Albrecht L, Schwan S. Blinded Comparative Study of Teicoplanin vs. Vancomycin for Gram-Positive Coccal Bacteremia: Failures of Therapy with Teicoplanin in Conventional Doses. VII<sup>th</sup> International Symposium on Staphylococci and Staphylococcal Infections, Stockholm Sweden, July 1992
75. Akhtar A, Eisenstadt J, Merline J, **Chandrasekar PH**, BMT Unit, Harper and Children's Hospitals. Viral Infections in Patient Undergoing Bone Marrow Transplantation (BMT). 7<sup>th</sup> International Symposium on Infections in the Immunocompromised Host, Boulder Colorado, June 1992
76. **Chandrasekar PH**, Sluchak J. Efficacy of Cefoperazone + Sulbactam (C + S) Against Cefoperazone Resistant E. coli Infection in Neutropenic Mice. 7<sup>th</sup> International symposium on Infections in the Immunocompromised Host, Boulder, Colorado, June 1992. Michigan September 1991

Published Abstracts (continued)

77. **Chandrasekar PH**, Sluchak J. Cefoperazone Plus Sulbactam vs. Cefoperazone Against Disseminated *E. coli* Infection in Neutropenic Mice. 92<sup>nd</sup> Annual Meeting of the American Society for Microbiology, New Orleans, Louisiana, May 1992
78. **Chandrasekar PH**, Gatny C, Bone Marrow Transplantation Team. Reduction of Candidal Colonization with Fluconazole in neutropenic Cancer Patients. Interscience conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, October, 1991
79. **Chandrasekar PH**, Gatny C, Kruse JA, Bone Marrow Transplantation (BMT) Team. Reduction in Use of Amphotericin with Fluconazole Prophylaxis in Neutropenic Cancer Patients. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, October, 1991
80. **Chandrasekar PH**, Sluchak J, Kruse JA, Bone Marrow Transplantation (BMT) Team. Quinolone Prophylaxis for Gut Decontamination during Bone Marrow Transplantation. Annual Meeting of the American College of Physicians, Traverse City, Michigan, September 1991
81. Gatny CM, **Chandrasekar PH**, Crane LR, Visscher D. Extrapulmonary Pneumocystosis in an AIDS Patient on Aerosol Pentamidine Prophylaxis. Annual Meeting of the American College of Physicians, Traverse City, Michigan, September 1991
82. Knoll-Vlachos S, **Chandrasekar PH**. Adult T-Cell Leukemia/Lymphoma In Detroit – A Non-Endemic Area for Human T Cell Lymphotropic Virus Type-I (HTLV-1). Annual Meeting of the American College of physicians, Traverse City, Michigan, September 1991
83. **Chandrasekar PH**, Gatny C, Kruse JA, Bone Marrow Transplant Team. Prospective Randomized, Double-Blind Study of Antifungal Prophylaxis for neutropenic Cancer Patients. Annual Meeting of the American college of Physicians, Traverse City.
84. Touchette MA, **Chandrasekar PH**, Milad MA, Edwards DJ. Differential Effects of Ketoconazole and Fluconazole on Phenytoin and Testosterone Concentrations in Man. Annual Meeting of the American College of Pharmacy, Minneapolis, Minnesota, August 1991
85. MacIntyre NR, Emmanuel G, Wedel NI, Gorelick KJ, **Xoma Sepsis Study Group**. E5 Antibody Improves Outcome from Multi-Organ Failure in survivors of Gram-Negative Sepsis. Annual Meeting of the Society of Critical Care Medicine, Washington, DC, May 1991
86. **Chandrasekar PH**, Sluchak JA. In Vitro Susceptibility of Gram-Positive and Gram-Negative Bacteremic Isolates from Cancer Patients. 91<sup>st</sup> Annual Meeting of the American Society for Microbiology, Dallas, Texas, May 1991
87. **Chandrasekar PH**, Sluchak JA: In Vitro Efficacy of Quinolones Against Multi-Resistant Aerobic Gram-Negative Bacillary Isolates from a Tertiary Care institution. 91<sup>st</sup> Annual Meeting of the American Society for Microbiology, Dallas, Texas, May 1991



Published Abstracts (continued)

88. Cheruku R, **Chandrasekar PH**, Ratanatharathron V, Sensenbrenner L. Invasive Aspergillosis with Concomitant Bacterial/Parasitic Infections. Regional Meeting American College of Physicians, Michigan Chapter and the Michigan Society of Internal Medicine, Traverse City, Michigan, October 1990
89. Mandanas RA, Tsai YH, Chiou CY, **Chandrasekar PH**. Infectious Complications Following Bone Marrow Transplantation in Autologous vs. Allogeneic Marrow Recipients. 6<sup>th</sup> International symposium on Infections in the Immunocompromised Host, Peebles, Scotland, June 1990
90. Martin MA, Wenzel RP, Gorelick KJ, **Xoma Sepsis Study Group**. Gram-Negative Sepsis – Presentation Therapy and Outcome in the 1980's. Annual Meeting of the Society of Critical Care Medicine, California, May-June 1990
91. Gorelick KJ, Schein RMH, MacIntyre NR, Emmanuel G, Bernard GR, **Xoma Sepsis Study Group**. Multicenter Trial of Antiendotoxin Antibody E5 in the Treatment of Gram-Negative Sepsis (GNS). Annual Meeting of the Society of Critical Care Medicine, California, May-June 1990
92. **Chandrasekar PH**, Sluchak JA. Newer vs. Older Agents Against Staphylococci. 90<sup>th</sup> Annual Meeting of the American Society for Microbiology, Anaheim, California, May 1990
93. **Chandrasekar PH**, Sluchak JA: In-Vitro Efficacy of Beta-Lactamase Inhibitors Plus Cefoperazone Against Multi-Resistant Gram-Negative Bacilli. 90<sup>th</sup> Annual Meeting of the American Society for Microbiology, Anaheim, California
94. **Chandrasekar PH**, Rolston KV, Sluchak JA, Dorman NJ. In-Vitro susceptibility of Staphylococci in Neutropenic Cancer Patients from Two Institutions. 90<sup>th</sup> Annual Meeting of the American society for Microbiology, Anaheim, California, May 1990
95. Sanchez V, **Chandrasekar PH**, Sobel JD. Diagnosing Systemic Candidiasis in Neutropenic Cancer Patients using a Candida Antigen Test. 90<sup>th</sup> Annual Meeting of the American Society for Microbiology, Anaheim, California, May 1990
96. Rudnick CA, **Chandrasekar PH**. A Comparative Study of Community Acquired Gram-Positive Bacteremia in HIV (+) vs. HIV (-) Intravenous Drug Abusers. American College of Physicians, Michigan chapter and the Michigan society of Internal Medicine, Traverse City, Michigan, September 1989
97. Mandanas RA, Tsai YH, Chiou CY, **Chandrasekar PH**. Infectious Complications Following Bone Marrow Transplantation vs. Allogeneic Marrow Recipients. American College of Physicians, Michigan Chapter and the Michigan Society of Internal Medicine, Traverse city, Michigan, September, 1989

Published Abstracts (continued)

98. Tsai YH, **Chandrasekar PH**. Infected Chylothorax in a Patient Treated with Radiotherapy for Vertebral Metastases from Prostatic Carcinoma. American college of Physicians, Michigan chapter and the Michigan society of Internal Medicine, Traverse City, Michigan September f1989
99. Tsai YH, **Chandrasekar PH**. Fatal Pseudomonal Maltophilia Bacteremia in a Patient with Leukemia. American College of Physicians, Michigan chapter and the Michigan Society of Internal Medicine, Traverse City, Michigan, September 1989
100. **Chandrasekar PH**, Sluchak JA. In Vitro Efficacy of Sulbactam vs. Clavulanic Acid in combination with Cefoperazone Against Cefoperazone Susceptible and Multi-Resistant Gram-Negative Bacteria. 16<sup>th</sup> International Congress of Chemotherapy, Jerusalem, Israel, June 11-16, 1989
101. Norello C, Knapp T, Cronin S, **Chandrasekar PH**. Nephrotoxicity in Bone Marrow Transplant Patients Receiving Aminoglycoside Plus Cyclosporine-A or Aminoglycoside alone. 16<sup>th</sup> International Congress of Chemotherapy, Jerusalem, Israel, June 11-16, 1989
102. **Chandrasekar PH**, Sluchak JA. Alternative Agents Against Methicillin-Resistant and Susceptible Staphylococcus aureus and staphylococcus epidermidis. 89<sup>th</sup> Annual Meeting of American Society for Microbiology, New Orleans, Louisiana, May 1989
103. **Chandrasekar PH**, Sluchak JA. Methicillin Resistant Staphylococci: Susceptibility to Clavulanic Acid (CA) Plus Betalactams and Betalactamase Quantitation. 8<sup>th</sup> Annual meeting of American Society for Microbiology, New Orleans, Louisiana, May 1989
104. **Chandrasekar PH**, Mathews M. Risk Factors for HIV Infection Among Parenteral Drug Abusers (PDA) in a Low Prevalence Area. Presented at the IV International Conference on AIDS, Stockholm, Sweden, June 12-16, 1988
105. **Chandrasekar PH**, Sluchak JA, Zurack MR. Post-Antibiotic Effect: Peptides & Newer Fluoroquinolones Against Methicillin Resistant Staphylococcus aureus. 88<sup>th</sup> Annual Meeting of American Society for Microbiology, Miami, Florida, May 1988
106. **Chandrasekar PH**, Sluchak JA, Hayden JF. Influence of Inoculum Size and Antibiotic Concentration on Post-Antibiotic Effect of Quinolones and Gentamicin Against Pseudomonas aeruginosa. 88<sup>th</sup> Annual Meeting of American Society for Microbiology, Miami, Florida, May 1988
107. **Chandrasekar PH**, Sluchak JA. Newer Agents Against Methicillin and/or Gentamicin Resistant and Susceptible Staphylococcus aureus & Staphylococcus epidermidis. 88<sup>th</sup> Annual Meeting of American Society for Microbiology, Miami, Florida, May 1988
108. Global JW, **Chandrasekar P H**, Greville HW. Opportunistic versus Non-Opportunistic Infection in HIV Infected Intravenous Drug Abuser. Annual Meeting of the American Thoracic Society, Las Vegas, Nevada, May 1988

Published Abstracts (continued)

109. Ham SD, Roszler MH, **Chandrasekar PH**, Darmody WR. Epidural Abscess in Intravenous Drug Abuser. Annual Meeting of the American Association of Neurological Surgeons, Toronto, Ontario, April 24-28, 1988
110. Gupta V, **Chandrasekar P H**. Rising Trend in Pulmonary Tuberculosis at a Detroit City Hospital. Presented at the Annual Meeting of the American College of Physicians, New York, New York, March 1988
111. **Chandrasekar PH**, Matthews M. Risk Factors for HIV Infection Among Parenteral Drug Abusers (PDA) in a Low Prevalence Area. *Clinical Research* 35(6), A857, October 1987
112. **Chandrasekar PH**, Sluchak J. Effect of Clavulanic Acid on Betalactam Activity Against Methicillin Susceptible and Resistant Staphylococcus aureus. 26<sup>th</sup> Interscience conference on Antimicrobial Agents and Chemotherapy, New York, New York, October 1987
113. Rybak MJ, Albrecht LM, **Chandrasekar PH**. Analysis of Vancomycin Nephrotoxicity. 26<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, New York, October 1987
114. Mehta R, **Chandrasekar PH**. Native Valve Staphylococcus epidermidis Endocarditis with Fatal Outcome. Regional Meeting, American College of Physicians, Michigan Chapter and Michigan Society of Internal Medicine, Traverse City, MI, September 1987
115. Gupta V, **Chandrasekar PH**. Rising Trend in Pulmonary Tuberculosis at a Detroit city Hospital. Regional Meeting American college of Physicians, Michigan Chapter and the Michigan Society of Internal Medicine, Traverse City, MI, September 1987'
116. **Chandrasekar PH**, Sluchak J, Levine D, Heyden J. Resistance Development among Staphylococci Following Exposure to Sub-Inhibitory Concentrations of Paldimycin. 87<sup>th</sup> Annual Meeting of American Society for Microbiology, Atlanta GA, March 1987
117. **Chandrasekar PH**, Rybak MJ, Albrecht LM. Retrospective Analysis of Vancomycin's Adverse Reactions in 135 Patients. 87<sup>th</sup> annual Meeting of American Society for Microbiology, Atlanta, GA, March 1987
118. **Chandrasekar PH**, Mehta R. Spinal Epidural Abscess (EA) in Intravenous Drug Abusers (IVDA). 26<sup>th</sup> Interscience Conference on antimicrobial Agents and Chemotherapy, New Orleans, LA, September – October 1986
119. **Chandrasekar PH**, Price S, Levine DP. Alternative Agents to B-Lactam/Vancomycin Against Methicillin Resistant (MR-) and Susceptible (MS-) Staphylococci. 26<sup>th</sup> Interscience conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September – October 1986

Published Abstracts (continued)

120. Jelinek MT, **Chandrasekar PH**. Actinomyces Odontolyticus Septicemia Following Urethral Instrumentation in Cancer Patient. Regional Meeting American College of Physicians, Michigan Chapter and Michigan Society of Internal Medicine, Traverse City, MI September 1986
121. Mehta R, **Chandrasekar PH**. Leprosy in a Laotian Immigrant with G6PD Deficiency. Epidemiological Trend of Leprosy in USA. Regional Meeting, American College of Physicians, Michigan Chapter and the Michigan Society of Internal Medicine, Traverse city, MI, September 1986
122. Palchaudhuri SP, Kumar R, Pal SC, **Chandrasekar PH**. Epidemic of Diarrhea in Wet Bengal, India Due to Ampicillin Resistant Shiga Bacillus. 86<sup>th</sup> Annual Meeting of American Society for Microbiology, Washington DC, March 1986
123. **Chandrasekar PH**, Crane LR. In Vitro Tests vs. Clinical Outcome in Pseudomonal Infection. Emergence of Betalactam Resistance Despite Synergy. 86<sup>th</sup> Annual Meeting of American Society for Microbiology, Washington DC, March 1986
124. **Chandrasekar PH**, Levine DP, Price L, Unowsky J. Efficacy of Coumermycin Teicoplanin in Experimental Endocarditis Due to Methicillin Resistant Staphylococcus aureus. 25<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, October 1985
125. Rolston K, **Chandrasekar PH**. Group G Streptococcal Infections. 25<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, October 1985
126. **Chandrasekar PH**, Hess JA, Mortiere M, Molinari JM. Treatment of Experimental Tichinosis with Ketoconazole and Mebendazole. 25<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, MN, October 1985
127. **Chandrasekar PH**, Chua D. Fungal Infections in Patients with Acquired Immune Deficiency Syndrome (AIDS). 6<sup>th</sup> International Meeting, International Society for STD Research, London, UK, August 1985
128. **Chandrasekar PH**, Mathews MF. Infections in Different Types of Intensive Care Units in An Acute Care Hospital. 14<sup>th</sup> Annual Educational & Scientific symposium of the society of Critical Care Medicine, Chicago, IL, May 1985
129. Mortiere M, **Chandrasekar P H**, Hess J, Molinari JA. Comparative Efficacy of Ketoconazole and Mebendazole in Experimental Tichinosis. 84<sup>th</sup> Meeting of American Society for Microbiology, Las Vegas, NV, March 1985
130. **Chandrasekar PH**, Palchaudhuri S, Pappas K, Svinarich D, Levine DP. Mechanism of Piperacillin Resistance in E. coli at the Detroit Receiving Hospital. 84<sup>th</sup> Meeting of American Society for Microbiology, Las Vegas, NV, March 1985

Published Abstracts (continued)

131. Arathoon E, **Chandrasekar PH**, Levine D. Bacteremic Pneumonia with Achromobacter xylosoxidans: Case Report and Review of Literature. Regional Meeting American College of Physicians, Michigan Chapter, Harbor Springs, MI, October 1984
132. Zervos M, Levine D, Frank R, **Chandrasekar PH**. Mycotic aneurysms in Intravenous Drug Users in the Wayne State University-Detroit Medical Center. 24<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 1984
133. Unowsky J, **Chandrasekar PH**, DeLorenzo W, Levine DP: In-Vitro and In-Vivo Activity of Coumermycin, Fusidic Acid, Cotrimoxazole and Vancomycin Against methicillin resistant Staphylococcus aureus (MRSA) Isolated in Detroit. 24<sup>th</sup> Interscience Conference on antimicrobial Agents and Chemotherapy, Washington DC, October 1984
134. Rolston K, **Chandrasekar PH**. Antimicrobial Tolerance in Group G and Group C Streptococci. 83<sup>rd</sup> Meeting of American Society for Microbiology, St. Louis, MO, 1984.
135. Sunstrum J, **Chandrasekar PH**, Levine DP, Rolston K. Group G Streptococcal Bacteremia: A Comparative Study. 83<sup>rd</sup> Meeting of American Society for Microbiology, St. Louis, MO, 1984
136. **Chandrasekar PH**, Levine DP, Stewart M. Bone and Joint Infections among Intravenous Drug Users in Detroit. 83<sup>rd</sup> Meeting of American Society for Microbiology, St. Louis, MO, 1984
137. Rolston KVI, **Chandrasekar PH**, Chokkavelu V, LeFrock JL. Group G Streptococcal Infections in Man. Regional Meeting American College of Physicians, Eastern and Western Pennsylvania and West Virginia, October 1983.
138. **Chandrasekar PH**, Rolston KVI, Kannangara DW, LeFrock JL, Binnick SA. Hot Tub Associated Pseudomonas Folliculitis. Regional Meeting, American College of Physicians, Eastern and Western Pennsylvania and West Virginia, October 1983
139. **Chandrasekar P H**, Kannangara DW, Chokkavelu V, LeFrock JL. Efficacy of Ketoconazole and Mebendazole in Trichinosis in Mice. 23<sup>rd</sup> Interscience Conference on antimicrobial Agents and Chemotherapy, Las Vegas, NV, October 1983
140. Chokkavelu V, **Chandrasekar PH**, Rolston K, LeFrock JL. Activity of Various Antimicrobials Against Methicillin-Resistant Staphylococcus aureus. 23<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, NV, October 1983
141. Rolston K, **Chandrasekar P H**, Chokkavelu V, LeFrock JL. In Vitro Activity of B-Lactams and Aminoglycosides against Pseudomonas aeruginosa. 21<sup>st</sup> Annual Meeting, Association for Gnotobiotics, Baltimore, June 1983

Published Abstracts (continued)

142. Smith B, Rolston K, **Chandrasekar PH**, LeFrock JL. Penetration of Cefmenoxime into Bile, Cerebrospinal Fluid, Sputum and other Sites. American College of Clinical Pharmacy Meeting, Washing, 1983
143. LeFrock JL, Molavi A, Carr B, Rolston K, Schell R, **Chandrasekar PH**, Kannangara DW. Meziocillin versus Cefoxitin in Intra-Abdominal and Pelvic Infections. 13<sup>th</sup> International congress, Vienna, Austria, 1983.
144. LeFrock JL, Molavi A, Smith B, Rosenberg M, Rolston K, **Chandrasekar PH**, Kannangara DW. Cefotaxime Therapy for the Treatment of Gram-Negative Meningitis. 13<sup>th</sup> International Congress of Chemotherapy, Vienna, Austria, 1983. Abstract to be published in Proceedings of the 13<sup>th</sup> International Congress of Chemotherapy.
145. LeFrock JL, Molavi A, McCloskey R, Rolston K, **Chandrasekar PH**, Smith BR, Kannangara DW, Carr B, Rosenberg M. Cefmenoxime Therapy of Skin and Skin Structure Infections. 13 International congress of Chemotherapy, Vienna Austria, 1983. Abstract to be published in Proceedings of the 13<sup>th</sup> International Congress of Chemotherapy.
146. **Chandrasekar PH**, Rolston K, Smith BR, LeFrock JL. Penetration of Ceftriaxone into Human Cerebrospinal Fluid. American College of Clinical Pharmacology. Washington, DC, April 1983
147. Rolston K, **Chandrasekar P H**, Smith BR, LeFrock JL. Cefmenoxime Penetration into Cerebrospinal fluid Across Non-Inflamed Meninges. American College of Clinical Pharmacology. Washington, DC, April 1983
148. **Chandrasekar PH**, Kannangara DW, Chokkavelu V. In-Vitro Activity of Beta-Lactams and Aztreonam Against Gentamicin Susceptible and Resistant P. aeruginosa. 83<sup>rd</sup> Meeting of American Society for Microbiology, New Orleans, LA, March 1983
149. **Chandrasekar PH**, Kannangara DW, Rolston K, Chokkavelu V. Comparative Efficacy of Four Antibiotics in Experimental Anaerobic Lung Abscess in Rabbits. 83<sup>rd</sup> Meeting of American Society for Microbiology, New Orleans, LA, March 1983
150. Rolston K, **Chandrasekar PH**, Chokkavelu V. In-Vitro Activity of Various Antimicrobials Against Methicillin Resistant Staphylococcus aureus. 83<sup>rd</sup> Meeting of American Society for Microbiology, new Orleans, LA March 1983
151. LeFrock J, Molavi A, Rolston K, Smith B, Schell R, Carr B, Oaks S, Kannangara DW, **Chandrasekar PH**, Lentnek A. Comparative clinical Evaluation of Meziocillin and Cefoxitin in Intra-Abdominal and Pelvic Infections. 22<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, Florida, October 1982

Published Abstracts (continued)

152. Molavi A, LeFrock JL, Rolston K, **Chandrasekar PH**, Henao L, Kannangara DW, Carr B, Schell R, Oaks S. Clinical and Microbiological Evaluation of Cefmenoxime. 22<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. Miami Beach, Florida, October
153. Molavi A, LeFrock JL, Rolston K, Smith B, Schell R, Carr B, **Chandrasekar PH**, Lentnek A, Oaks S. Comparison of Mezlocillin and Cefoxitin. IN: Proceedings of the 2<sup>nd</sup> International Symposium of Acylureidopenicillins, Reeves DS and Weuta H (ads) London. Excerpta Medica Amsterdam 1106-115, 1982
154. **Chandrasekar PH**, Francisco M, LeFrock JL. In Vitro comparison of Cefsulodin, Other Cephalosporins and New Penicillins against P. aeruginosa. 82<sup>nd</sup> Meeting of American Society for Microbiology, Atlanta, Georgia, 1982
155. LeFrock JL, Molavi A, Rolston KVI, **Chandrasekar PH**, Smith B, Kannangara DW, Lentnek A. Comparative Study of Ceftizoxime and Cefamandole in the Treatment of Bronchopulmonary Infections. A Review of Newer Cephalosporins. The Role of Ceftizoxime. Bermuda 1981
156. A comparative Study of Liver Function Tests in Cirrhosis and Tuberculosis of the Indian Society of Gastroenterology, India, 1976